

Optimize PRO Study

NCT: 04091048

Study Protocol/Document Date: 21Jul2019

Optimize PRO Clinical Investigation Plan

Version 3.0

Page 1 of 82

Medtronic

Medtronic

Clinical Investigation Plan

Clinical Investigation Plan/Study Title	Optimize PRO TAVR Post Market Study
Study Product Name	Medtronic Evolut PRO™ System
Sponsor/Local Sponsor	Medtronic, Inc. Coronary and Structural Heart Clinical [REDACTED] Medtronic of Canada Ltd. [REDACTED]
Document Version	3.0, 21 July 2019
Co-Principal Investigators	Dr. Kendra Grubb Emory University Hospital [REDACTED] Dr. Steven Yakubov Riverside Methodist Hospital / Ohio Health Research Institute [REDACTED]
Confidentiality Statement The information contained in this document is confidential and the proprietary property of Medtronic. Any distribution, copying, or disclosure without the prior written authorization of Medtronic is strictly prohibited. Persons to whom the information is disclosed must know that it is confidential and that it may not be further disclosed by them.	

Medtronic Confidential

This document is electronically controlled

056-F275, v A Clinical Investigation Plan Template

1. Investigator Statement

Study product Name	Medtronic Evolut™ PRO
Sponsor	Medtronic Coronary and Structural Heart Clinical
Version Number/Date	3.0, 21 July 2019
<p>I have read the protocol, including all appendices, and I agree that it contains all necessary details for me and my staff to conduct this study as described. I will conduct this study as outlined herein and will make a reasonable effort to complete the study within the time designated.</p> <p>I agree to comply with local and internal institutional requirements including the protocol, GCP, and ethical principles that have their origin in the Declaration of Helsinki.</p> <p>I agree to ensure that the confidential information contained in this document will not be used for any purpose other than the evaluation and conduct of the clinical study without the prior written consent of Medtronic.</p> <p>I will provide all study personnel under my supervision copies of the protocol and access to all information provided by Medtronic. I will discuss this material with them to ensure that they are fully informed about the products and the study.</p>	
Investigator's Signature:	
Investigator's Name:	
Institution:	
Date:	



Table of Contents

1. Investigator Statement.....	2
Table of Contents	3
2. Glossary.....	7
3. Synopsis	9
4. Introduction.....	11
4.1. Background and Rationale.....	11
4.2. Purpose.....	12
5. Objectives and Endpoints	12
5.1. Objectives	12
5.1.1. Primary Objective	12
5.2. Endpoints.....	12
5.2.1. Primary Endpoint	12
5.2.2. Secondary Endpoints	12
5.2.3. Additional Exploratory Endpoints.....	12
5.2.4. Rationale	13
6. Study Design.....	13
6.1. Duration.....	13
6.2. Trial Organization	13
6.2.1 Participating Sites	13
6.2.2. Site Principal Investigator	14
6.2.2 Heart Team	14
6.2.3 Publication Committee	14
6.2.4 Trial Training	15
7. Product Description	15
7.1 Description of Devices	15
7.1.2 Medtronic Evolut PRO System.....	15
7.2. Manufacturer.....	19
7.3. Intended Population.....	19



7.4. Product Training Requirements.....	20
7.5. Product Labeling, Tracking, and Accountability	20
7.6. Product Storage	20
8. Selection of Subjects	20
8.1 Study Population	20
8.2. Subject Enrollment	20
8.3. Inclusion Criteria.....	21
8.4. Exclusion Criteria	21
9. Study Procedures	22
9.1 Schedule of Events.....	22
9.1.1 Screening Procedures	23
9.1.2 Enrollment	23
9.1.3 Implant Procedure (TAVR)	24
9.1.4 Prior to Discharge	25
9.1.5 Follow-Up Evaluations	25
9.1.6 Additional Evaluations for Pacemaker Implants.....	27
9.1.7 Missed Follow-Up Visits.....	27
9.1.8 Core Labs.....	27
9.1.9 Informed Consent	27
9.2 Revisions in Patient Information and Informed Consent Form.....	28
9.3 Assessment of Efficacy	28
9.4 Assessment of Safety.....	29
9.4.1 Serious Adverse Events and Device Deficiencies.....	29
9.5 Recording Data	29
9.5.1 Source Documents.....	29
9.6 Deviation Handling	30
9.7 Subject Withdrawal or Discontinuation	31
10 Risks and Benefits	31
10.1 Potential Risks.....	31



10.2 Potential Benefits	31
10.3 Risk-Benefit Rationale	32
10.3.1 Measures to Mitigate Risks in the Trial Subjects	32
10.3.2 Alternatives	32
10.3.3 Results from the Risk Analysis and Justification for the Study	32
11 Adverse Events and Device Deficiencies.....	33
11.1 Definitions/Classifications	33
11.1.1 Evaluation and Documentation of Serious Adverse Events	33
11.1.2 Evaluation and Documentation of Device Deficiencies	35
11.2 Reporting of Serious Adverse Events	35
11.3 Emergency Contact Details for Reporting SAE and Device Deficiencies	35
12 Data Review Committees	35
12.1 Clinical Events Committee	35
13. Statistical Design and Methods.....	36
13.1 Analysis Populations.....	36
13.1.1 Enrolled Population.....	36
13.2 Description of Baseline Variables	36
13.3 Primary Analysis	37
13.3.1 Primary Endpoint	37
13.4 Sample Size	37
13.5 Secondary Endpoints	37
13.6 Additional Exploratory Endpoints.....	37
13.7 Missing Data	38
14. Ethics and Regulatory Compliance	38
15. Study Administration	39
15.1. Monitoring.....	39
15.2. Data Management.....	39
15.3. Direct Access to Source Data/Documents.....	40
15.4. Confidentiality	40



15.5.	Liability	40
15.6.	CIP Amendments	40
15.7.	Record Retention.....	41
15.8.	Publication and Use of Information	41
15.9.	Suspension or Early Termination.....	41
15.9.1	Suspension or Early Termination of the Trial.....	41
15.9.2	Suspension or Early Termination of a Trial Site	41
16.	Other Institutions and Professional Services	42
17.	Version History	42
18.	References.....	45
19.	Appendices	47
19.1	Conduction Disturbance Management	47
19.2	Quality of Life Questionnaires	51
19.3	Echocardiography Procedure	51
19.3.1	Required Exams.....	51
19.3.2	General Imaging and Recording Procedures.....	51
19.3.3	List of Recommended Images	52
19.3.4	Data Requirements	54
19.3.5	Acquisition of Key Variables	55
19.3.6	Core Lab Analysis.....	64
19.4	Recommended MSCT Procedures	66
19.4.1	General requirements	67
19.4.2	ECG-gated contrast enhanced scan of aortic root	67
19.4.3	Anatomic suitability and valve size selection.....	72
19.5	Resheath and Recapture Definitions	72
19.6	Endpoint Definitions.....	73

2. Glossary

Term	Definition
2D	Two Dimensional
AE	Adverse Event
ADE	Adverse Device Effect
AF	Atrial Fibrillation
AR	Aortic Regurgitation
AS	Aortic Stenosis
AVR	Aortic Valve Replacement
BAV	Balloon Aortic Valvuloplasty
BNP	Brain Natriuretic Peptide
CEC	Clinical Events Committee
CIP	Clinical Investigation Plan
CLS	Compression Loading System
CHB	Complete heart block
CRF	Case Report Form
CRO	Contract Research Organization
CT	Computed Tomography
CVA	Cerebrovascular Accident
DCS	Delivery Catheter System
ECG	Electrocardiogram
e-CRF	Electronic Case Report Form
EDC	Electronic Data Capture

Term	Definition
EF	Ejection Fraction
EQ-5D	European Quality of Life – 5 Dimensions
HAVB	High Degree Atrioventricular Block
ICF	Informed Consent Form
IRB/REC	Institutional Review Board/Research Ethics Board
IFU	Instructions For Use
ITT	Intent-to-treat
KCCQ	Kansas City Cardiomyopathy Questionnaire
LBBS	Left Bundle Branch Block
LS	Loading System
MI	Myocardial Infarction
MRS	Modified Rankin Score
MSCT	Multi Slice Computed Tomography
NYHA	New York Heart Association
TAV	Transcatheter Aortic Valve
PCI	Percutaneous Coronary Intervention
TAVR	Transcatheter Aortic Valve Replacement
QoL	Quality of Life
RBBB	Right Bundle Branch Block
SAE	Serious Adverse Event
SAVR	Surgical Aortic Valve Replacement
SOP	Standard Operating Procedures
STS	Society of Thoracic Surgeons

Term	Definition
TEE	Transesophageal Echocardiography

3. Synopsis

Title	Optimize PRO Study
Devices	<ul style="list-style-type: none">• Medtronic Evolut™ PRO Transcatheter Aortic Valve (TAV)• Medtronic EnVeo™ PRO Delivery Catheter System (DCS) with EnVeo™ InLine Sheath or EnVeo™ R DCS with EnVeo™ InLine Sheath• Medtronic EnVeo™ PRO Loading System (LS) or EnVeo™ R LS
Sponsor	Medtronic Coronary and Structural Heart Clinical Research
Co-Principal Investigators	Dr. Steven Yakubov and Dr. Kendra Grubb
Primary Objective	The purpose of this study is to collect clinical evidence on valve performance and procedural outcomes associated with an “optimized” TAVR care pathway and using the Evolut™ PRO device
Primary Endpoint	Rate of all-cause mortality or all-stroke at 30 days
Secondary Endpoints	<ul style="list-style-type: none">• Median days from index procedure to discharge• Percentage of subjects with \geq moderate aortic regurgitation (AR) at discharge.• Rate of pacemaker implant for new onset or worsening conduction disturbance at 30 days
Additional Exploratory Endpoints	<ul style="list-style-type: none">• 30-day and 1-year hospital re-admission rates• 1-year composite of all-cause mortality or all-stroke
Study Design	Post-market, multi-center, prospective, non-randomized
Sample Size	Up to 46 sites in the United States and Canada with up to 400 subjects
Patient Population	Subjects with severe, symptomatic aortic stenosis (AS) necessitating valve replacement
Duration	Total study duration is estimated to be 2 years (time from first subject implanted to one-year follow-up on last subject implanted)
Key Inclusion Criteria	<ul style="list-style-type: none">• Acceptable candidate for treatment with the Evolut PRO system in accordance with the Instructions for Use and local regulations;

	<ul style="list-style-type: none"> • Subject is symptomatic from his/her aortic valve stenosis, as demonstrated by New York Heart Association (NYHA) Functional Class II or greater; • Subject and the treating physician agree that the subject will return for all required post procedure follow-up visits; • Anatomically suitable for transfemoral TAVR with the Medtronic TAVR system; • Subject meets the legal minimum age to provide Informed Consent based on local regulatory requirements;
Key Exclusion Criteria	<ul style="list-style-type: none"> • Contraindicated for treatment with the Evolut PRO system in accordance with the Instructions for Use • Anatomically not suitable for the Evolut™ PRO system; • Any percutaneous coronary or peripheral interventional procedure performed within 30 days prior to enrollment; • Previous aortic valve replacement; • Reduced ventricular function with left ventricular ejection fraction (LVEF) < 35% as measured by resting echocardiogram; • Frailty assessments identify: <ul style="list-style-type: none"> ○ Subject is <80 years of age and three or more of the following apply; OR subject is ≥ 80 years of age and two or more of the following apply <ul style="list-style-type: none"> ▪ Wheelchair bound ▪ Resides in an institutional care facility (eg. nursing home, skilled care center) ▪ Body Mass Index <20kg/m² ▪ Grip strength <16kg ▪ Katz Index score ≤4 ▪ Albumin <3.5 g/dL • Bicuspid valve verified; • Aortic root angulation (angle between plane of aortic valve annulus and horizontal plane/vertebrae) > 70°. • Implanted with pacemaker or ICD; • Prohibitive left ventricular outflow tract calcification; • Estimated life expectancy of less than 12 months due to associated non-cardiac co-morbid conditions;

	<ul style="list-style-type: none"> • Other medical, social, or psychological conditions that in the opinion of the Investigator precludes the subject from appropriate consent, adherence to the protocol required follow-up exams; • Currently participating in an investigational drug or another device trial (excluding registries); • Need for emergency surgery for any reason; • Subject is less than legal age of consent, legally incompetent, or otherwise vulnerable.
Study Procedures and Assessments	<ul style="list-style-type: none"> • Clinical assessment at baseline, discharge, 30 days, and 1 year • Transthoracic echo at baseline, discharge, and 1 year • Multi-Detector Computed Tomography at baseline • Quality of Life pre and post-procedure, 30 days, and 1 year • 12-lead ECG at pre and post-procedure, 30 days, and 1 year

4. Introduction

4.1. Background and Rationale

Transcatheter aortic valve replacement (TAVR) has been shown to be a safe and effective treatment for patients with severe aortic stenosis who are at extreme, high, or intermediate surgical risk⁽¹⁻³⁾. Since CoreValve™ became commercially approved in the United States by the Food and Drug Administration (FDA) in 2014, the procedure and valve iterations have become increasingly efficient with reducing complications. The Evolut™ PRO valve's outer pericardial wrap has shown to enhance annular sealing resulting in a decrease in paravalvular leak⁽⁴⁾. There is also a growing shift towards optimizing the TAVR care pathway by protocolizing the pre, peri, and post procedure assessments. This optimization can further increase the efficiency of the procedure and subsequently decrease the length of hospital stay and reduce health care costs^(5,6).

This procedural efficiency has not translated to a reduction in permanent pacemaker implantation (PPI) rates. Rates have decreased with newer generation TAVR valves, however, variability continues⁽⁷⁾. There is a lack of consensus regarding the management of post-TAVR conduction abnormalities leading towards heterogenous PPI rates across institutions and potentially unnecessary pacemakers for abnormalities that could have resolved intrinsically over time^(8,9). Previous studies indicate most of high degree atrioventricular block (HAVB) and left bundle branch block (LBBB) occur prior to hospital discharge, and early monitoring is key to identifying and managing persistent TAVR-induced conduction abnormalities^(10,11).

The objective of this study is to collect outcome data on valve performance and a pre-specified TAVR care pathway. Additionally, this study will protocolize the management of the post-TAVR conduction

disturbances and evaluate whether a consistent deployment technique will reduce the variability of new onset conduction disturbances.

4.2. Purpose

The purpose of this study is to collect clinical evidence on valve performance and procedural outcomes associated with an “optimized” TAVR care pathway and using the Evolut PRO device.

5. Objectives and Endpoints

5.1. Objectives

5.1.1. Primary Objective

The primary objective of this study is to collect clinical evidence on valve performance and procedural outcomes associated with an “optimized” TAVR care pathway and using the Evolut PRO device.

5.2. Endpoints

The following endpoints will be used to evaluate the primary trial objectives:

5.2.1. Primary Endpoint

The primary endpoint is the rate of all-cause mortality or all-stroke at 30 days.

5.2.2. Secondary Endpoints

The following are the secondary endpoints:

- Median days from index procedure to discharge
- Percentage of subjects with \geq moderate aortic regurgitation (AR) at discharge
- Rate of pacemaker implant for new onset or worsening conduction disturbance at 30 days

5.2.3. Additional Exploratory Endpoints

The following are additional exploratory endpoints:

- 30-day and 1-year hospital re-admission rates
- 1-year composite of all-cause mortality or all-stroke

5.2.4. Rationale

The basis for the selection of these study endpoints include:

- Clinically relevant outcomes of the Evolut PRO device
- In accordance with objectively measuring the efficacy of an optimized care pathway for TAVR subjects
- Objectively defined and measurable in the majority of subjects
- Consistent with current recommendations for endpoints in TAVR clinical studies⁽¹²⁾

6. Study Design

This is a post market, multi-center, prospective, non-randomized study. The study methods include the following measures to minimize potential sources of bias:

- An external, independent Clinical Events Committee (CEC) will review and adjudicate, at minimum, all deaths and endpoint related adverse events. Safety endpoint results will be based on CEC adjudications.
- All sites will follow a standardized protocol for acquisition of echocardiographic endpoint data.
- Core labs will evaluate all echocardiograms and ECGs. Echocardiographic trial endpoint results will be based on Core Lab assessments.
- Subjects will be screened to confirm eligibility for enrollment with pre-defined inclusion and exclusion criteria.

6.1. Duration

The enrollment period is estimated to be less than 12 months and subjects will be followed for up to one year post index procedure; therefore, the estimated total duration of the study (first subject enrolled to last subject completing his/her last follow-up exam) is estimated to be less than 2 years.

6.2. Trial Organization

6.2.1 Participating Sites

This trial may be conducted at up to 46 sites in the United States and Canada. Investigative sites will meet the following criteria:

- The site will have extensive facility experience with TAVR. Operator 1 and Operator 2 must meet the minimum of ≥ 20 TAVR procedures in the prior year, or ≥ 40 TAVR procedures in the prior two years.
- The site will have the presence or capacity of establishing an investigative team consisting of the following:

- Minimum of 2 TAVR implanters with expertise in transcatheter aortic valve replacement as noted above
- Electrophysiologist
- Echocardiographer
- Trial coordinator

6.2.2. Site Principal Investigator

Each site will have a Principal Investigator (PI) who is a TAVR implanter among the Heart Team. The PI will have overall responsibility for the conduct of the study at the site, including protecting the rights, safety, and welfare of the study subjects at their site, the integrity of the trial data generated by their site, and for ensuring the trial is conducted in compliance with the Clinical Investigation Plan and IRB/REB requirements.

6.2.2 Heart Team

Each site will utilize a local Heart Team to assess eligibility of the prospective subject for the trial according to the site's standard process and payer requirements.

At a minimum, the local Heart Team should include the TAVR implanter. The site PI may also serve as a member of the Heart Team.

6.2.3 Publication Committee

A Publication Committee will provide direction and support in the development of clinical publications. The Publication Committee will consist of steering committee members. The Publication Committee will be responsible to:

- Define the publication plan
- Review, approve, and prioritize publication proposals
- Provide input on the scientific merit and clinical relevance of ancillary publications
- Identify the manuscript/abstract first author(s)/writer(s)/presenter(s)
- Review publications prior to submission

The Committee will be in charge of publication efforts until the completion of the primary endpoint. All publication activities post the primary endpoint will be facilitated by the Medtronic TAVR Global Evidence Committee.

6.2.4 Trial Training

Prior to participating, center activation, or subsequent involvement in study activities, Medtronic will provide training to the investigative team on the trial methods, procedures, and requirements. Training may be conducted via site initiation visits, investigator meetings, and/or other media sessions. Medtronic will maintain documentation of these training sessions. Additionally, Medtronic representative(s) may be present at each site's implant procedures as part of the ongoing procedure support process.

7. Product Description

7.1 Description of Devices

7.1.2 Medtronic Evolut PRO System

The Medtronic Evolut PRO System is a TAVR implantation system comprised of the following 3 components (Table 1):

- Medtronic Evolut PRO TAV
- Medtronic EnVeo PRO DCS with EnVeo InLine Sheath or EnVeo R DCS with EnVeo InLine Sheath
- Medtronic EnVeo PRO LS or EnVeo R LS

The system components for the study are shown in Figure 1 and detailed descriptions provided in Sections 7.2.1.1, 7.2.1.2, and 7.2.1.3.

Table 1. Evolut PRO™ Systems Components

Component	US Model Number	Canadian Model Number	Size (mm)	Aortic Annulus Diameter (mm)
Medtronic Evolut PRO TAV	EVOLUTPRO-23-US	EVOLUTPRO-23	23	18 – 20
	EVOLUTPRO-26-US	EVOLUTPRO-26	26	20 – 23
	EVOLUTPRO-29-US	EVOLUTPRO-29	29	23 – 26
EnVeo R DCS with EnVeo InLine Sheath (20 Fr/16eFr)	ENVEOR-N-US	ENVEOR-N	Used with 23, 26, and 29 mm TAVs	Not applicable
EnVeo PRO DCS with EnVeo InLine Sheath (20 Fr/16eFr)	ENVPRO-16-US	ENVPRO-16	Used with 23, 26, and 29 mm TAVs	Not applicable

Medtronic Confidential

Optimize PRO Clinical Investigation Plan

Version 3.0

Page 16 of 82

Medtronic

EnVeo R LS	LS-MDT2-23-US	LS-MDT2-23	Used with 23 mm TAV	Not applicable
	LS-MDT2-2629-US	LS-MDT2-2629	Used with 26 and 29 mm TAV	Not applicable
EnVeo PRO LS	L-ENVPRO-1623US	L-ENVPRO-1623	Used with 23 mm TAV	Not applicable
	L-ENVPRO-16-US	L-ENVPRO-16	Used with 26 and 29 mm TAV	Not applicable

A




B



C



D



E



Medtronic Confidential

This document is electronically controlled

056-F275, v A Clinical Investigation Plan Template

Figure 1. (A) Evolut PRO TAV; **(B)** EnVeo PRO DCS and EnVeo InLine Sheath; **(C)** EnVeo R DCS and EnVeo InLine Sheath **(D)** EnVeo R LS **(E)** EnVeo PRO LS

7.1.2.1 Medtronic Evolut PRO Transcatheter Aortic Valve

The Evolut PRO TAV is available in 3 sizes (23, 26, 29 mm), covering an aortic annulus diameter of 18 to 26 mm. For the 26mm and 29mm bioprotheses: If the patient's annulus diameter is within 0.5 mm of the upper or lower bound of the range, use of the larger valve size can be considered, provided additional dimensional criteria as outlined in the CIP are met. The TAV is comprised of 3 leaflets, a sealing skirt, and outer tissue wrap constructed from glutaraldehyde-fixated porcine pericardium, sewn to a compressible and self-expandable Nitinol support frame. The TAV is processed with an anti-mineralization treatment of AOA, a compound derived from oleic acid, a naturally occurring long-chain fatty acid.

7.1.2.2 Medtronic EnVeo PRO Delivery Catheter System with EnVeo InLine Sheath

The EnVeo PRO DCS facilitates the placement of the TAV within the annulus of the aortic valve. The catheter assembly is flexible and compatible with a 0.035 in (0.889 mm) guidewire. The distal (deployment) end of the system features an atraumatic, radiopaque catheter tip and a capsule that covers and maintains the bioprosthesis in a crimped position. The capsule includes a distal flare to enable full recapture of the bioprosthesis after partial deployment. A stability layer is fixed at the handle and extends down the outside of the catheter shaft. It provides a barrier between the retractable catheter and the introducer sheath and vessel walls, thus enabling the catheter to retract freely. Updates to the system include redesign of the distal tip of the DCS.

The EnVeo InLine Sheath is assembled over the stability layer, which functions as a hemostatic introducer sheath and minimizes the access site size to the capsule diameter. The InLine Sheath for the 23 mm, 26 mm, and 29 mm Evolut PRO system is compatible with a 20 Fr introducer.

The DCS consists of a catheter with an integrated handle to provide the user with accurate and controlled deployment. The handle is on the proximal end of the catheter and is used to load, deploy, recapture, and reposition the bioprosthesis. The handle features a gray front grip used to stabilize the system. The blue actuator turns to deploy the bioprosthesis precisely. Arrows on the actuator indicate the direction of rotation required to deploy the bioprosthesis. If desired, the blue actuator can be turned in the opposite direction to recapture the bioprosthesis if the radiopaque capsule marker band has not yet reached the distal end of the spindle. The blue actuator also features a trigger, which can be engaged to make macro adjustments to the capsule position. A blue hand rest connects to the blue actuator. The end of the handle features a tip-retrieval mechanism, which can be used to withdraw the catheter tip to meet the capsule after the device has been fully deployed.

The catheter packaging contains an integrated loading bath and a removable tray with 3 rinsing bowls for loading and rinsing the bioprosthesis. The integrated loading bath features a mirror, which aids in accurate placement of the bioprosthesis frame paddles during loading. In addition, the device packaging is swiveled and secured to facilitate the bioprosthesis loading procedure.

7.1.2.3 Medtronic EnVeo R Catheter Delivery System with EnVeo InLine Sheath

The EnVeo R catheter delivery system facilitates the placement of the TAV within the annulus of the aortic valve. The catheter assembly is flexible and compatible with a 0.035 in (0.889 mm) guidewire. The distal (deployment) end of the system features an atraumatic, radiopaque catheter tip and a capsule that covers and maintains the bioprosthesis in a crimped position. The capsule includes a distal flare to enable full recapture of the bioprosthesis after partial deployment. A stability layer is fixed at the handle and extends down the outside of the catheter shaft. It provides a barrier between the retractable catheter and the introducer sheath and vessel walls, thus enabling the catheter to retract freely.

The EnVeo InLine Sheath is assembled over the stability layer, which functions as a hemostatic introducer sheath and minimizes the access site size to the capsule diameter. The EnVeo InLine Sheath for the 23 mm, 26 mm, and 29 mm Evolut PRO system is compatible with a 20 Fr introducer.

The delivery catheter system consists of a catheter with an integrated handle to provide the user with accurate and controlled deployment. The handle is on the proximal end of the catheter and is used to load, deploy, recapture, and reposition the bioprosthesis. The handle features a gray front grip used to stabilize the system. The blue actuator turns to deploy the bioprosthesis precisely. Arrows on the actuator indicate the direction of rotation required to deploy the bioprosthesis. If desired, the blue actuator can be turned in the opposite direction to recapture the bioprosthesis if the radiopaque capsule marker band has not yet reached the distal end of the spindle. The blue actuator also features a trigger, which can be engaged to make macro adjustments to the capsule position. A blue hand rest connects to the blue actuator. The end of the handle features a tip-retrieval mechanism, which can be used to withdraw the catheter tip to meet the capsule after the device has been fully deployed.

The catheter packaging contains an integrated loading bath and a removable tray with 3 rinsing bowls for loading and rinsing the bioprosthesis. The integrated loading bath features a mirror, which aids in accurate placement of the bioprosthesis frame paddles during loading. In addition, the device packaging is swiveled and secured to facilitate the bioprosthesis loading procedure.

7.1.2.4 Medtronic EnVeo R Loading System

The EnVeo R LS facilitates manual loading of the TAV into the deployment sheath capsule of the DCS by gradually reducing the diameter of the bioprosthesis radially to an optimal diameter. The manual loading is performed during the procedure prior to implantation. The loading procedure is performed while immersing the LS, the TAV, and the distal end of the DCS in cold sterile saline.

The EnVeo R LS was designed with ribs on the interior surface of the cone designed to decrease the friction between the TAV tissue wrap on the inflow cone during loading. There are two loading system models; one for the 23 mm TAV and another for the 26 mm and 29 mm TAV sizes.

7.1.2.5 EnVeo PRO Loading System

Similar to the EnVeo R LS, the EnVeo PRO LS is a system of reduction cones and tubing designed to gradually reduce the diameter of the TAV radially to an optimal diameter to facilitate manual loading of the Evolut PRO TAV into the deployment sheath capsule of the EnVeo R DCS or EnVeo PRO DCS. The EnVeo PRO loading system incorporates minor modifications including a change to the capsule guide tube (CGT) to include a locking collar, which reduces the ability of the user to load the TAV with a paddle in the incorrect position by preventing movement of the frame paddles once positioned in the spindle pockets. Additionally, manufacturing process changes and a minor design and material change, including the color differentiation between the two loading system sizes, was implemented on the catheter tip guide tube (TGT) components. A third modification is to the inner diameter of the inflow ring designed to allow multiple TAVs to seat securely into the inflow ring.

7.2. Manufacturer

The legal manufacturer and design site of the Evolut PRO system is as follows:

Medtronic CoreValve LLC



7.3. Intended Population

The study population includes patients with symptomatic native aortic valve stenosis necessitating valve replacement. Patients who undergo an emergency procedure should not be included in this study.

7.4. Product Training Requirements

The Evolut PRO device will be used within the local approved indication, with exception to any exclusion criteria in this protocol, and obtained by the study sites according to standard hospital procedures for commercial products. Local existing approved procedures for commercial product regarding training, distribution, shipment, storage, handling, return of these devices will be followed.

7.5. Product Labeling, Tracking, and Accountability

Subjects enrolled in this study will be treated using commercial product. Device lot and serial numbers, as applicable, will be collected in the Device Identification CRF. As this is not an investigational trial, Product Accountability Logs (PALs) will not be utilized. Sites will follow their institutional standard practice for device ordering and replenishment of commercial product for use in this study.

In Canada, only system components licensed for sale by Health Canada will be used in the study.

7.6. Product Storage

Sites will follow their institutional standard practice for storing commercial TAVR product.

8. Selection of Subjects

8.1 Study Population

The study population includes patients with symptomatic native aortic valve stenosis that necessitates valve replacement who meet the criteria for on-label use of the Evolut PRO system in accordance with Instructions for Use and local regulations.

8.2. Subject Enrollment

This study will involve up to 400 subjects based on the number of subjects with an attempted TAVR procedure among all active sites. To ensure a widespread distribution of data and to minimize bias in the study results, no site will implant more than 50 subjects without prior authorization from Medtronic. Subjects who exit from the study after implantation will not be replaced.

8.2.2. Roll-In Subjects

For all participating centers, the first three subjects implanted will be considered “roll-in” subjects. The purpose of the roll-in subjects is to provide Investigators the time for training and familiarization with the

protocolized implant technique. The Training and Education team will review recommendations made by the Steering Committee for transition of sites from roll-in phase to as treated analysis phase.

Roll-in subjects will complete in-clinical follow-up evaluations as noted in section 9.1.5 Follow-Up Evaluations however the results for the roll-in population will be analyzed separately from the primary analysis cohorts.

8.3. Inclusion Criteria

Prospective subjects must meet all of the following inclusion criteria to be eligible for randomization:

1. Acceptable candidate for treatment with the Evolut PRO system in accordance with the Instructions for Use and local regulations;
2. Subject is symptomatic from his/her aortic valve stenosis, as demonstrated by New York Heart Association (NYHA) Functional Class II or greater;
3. Subject and the treating physician agree that the subject will return for all required post procedure follow-up visits;
4. Anatomically suitable for transfemoral TAVR with the Medtronic TAVR system;
5. Subject meets the legal minimum age to provide Informed Consent based on local regulatory requirements.

8.4. Exclusion Criteria

Subjects are not eligible for study participation if they meet ANY of the following exclusion criteria:

1. Contraindicated for treatment with the Evolut PRO system in accordance with the Instructions for Use
2. Anatomically not suitable for the Evolut PRO system;
3. Any percutaneous coronary or peripheral interventional procedure performed within 30 days prior to enrollment;
4. Reduced ventricular function with left ventricular ejection fraction (LVEF) < 35% as measured by resting echocardiogram;
5. Previous aortic valve replacement;
6. Frailty assessments identify:
 - Subject is <80 years of age and three or more of the following apply; OR subject is \geq 80 years of age and two or more of the following apply
 - Wheelchair bound
 - Resides in an institutional care facility (e.g. nursing home, skilled care center)

- Body Mass Index <20kg/m²
 - Grip strength <16kg
 - Katz Index score ≤4
 - Albumin <3.5 g/dL
7. Bicuspid valve verified;
 8. Aortic root angulation (angle between plane of aortic valve annulus and horizontal plane/vertebrae) > 70°.
 9. Implanted with pacemaker or ICD;
 10. Prohibitive left ventricular outflow tract calcification;
 11. Estimated life expectancy of less than 12 months due to associated non-cardiac co-morbid conditions;
 12. Other medical, social, or psychological conditions that in the opinion of the Investigator precludes the subject from appropriate consent or adherence to the protocol required follow-up exams;
 13. Currently participating in an investigational drug or another device trial (excluding registries);
 14. Need for emergency surgery for any reason.
 15. Subject is less than legal age of consent, legally incompetent, or otherwise vulnerable*.

** Notes: Vulnerable subjects include individuals whose willingness to volunteer in a clinical investigation could be unduly influenced by the expectation, whether justified or not, of benefits associated with participation or of retaliatory response from senior members of a hierarchy in case of refusal to participate. EXAMPLE Individuals with lack of or loss of autonomy due to immaturity or through mental disability, persons in nursing homes, children, impoverished persons, subjects in emergency situations, ethnic minority groups, homeless persons, nomads, refugees, and those incapable of giving informed consent. Other vulnerable subjects include, for example, members of a group with a hierarchical structure such as university students, subordinate hospital and laboratory personnel, employees of the sponsor, members of the armed forces, and persons kept in detention.⁽¹³⁾*

9. Study Procedures

9.1 Schedule of Events

Follow-up protocol required evaluations should be performed at the trial site. The protocol required evaluations for each trial interval are listed as follows and summarized in Table 2.

9.1.1 Screening Procedures

The following assessments must be completed within 12 weeks prior to TAVR index procedure unless otherwise indicated:

- Clinical assessment, history, and concomitant medications
 - Physical examination including height, weight, systolic and diastolic blood pressure, and body surface area.
 - 5-Meter Gait Speed
 - Grip Strength
- NYHA classification
- MDCT angiogram – *within 1 year prior to procedure*
- TTE – *within 10 weeks prior to procedure*
- Heart Team eligibility assessment
- 12-lead ECG – *within 48 hours prior to procedure*
- Laboratory tests – glomerular filtration rate (GFR), hemoglobin, international normalized ratio (INR) for subjects on warfarin, and serum creatinine
- Modified Rankin Score – conducted by certified site personnel
- Quality of Life Questionnaires
 - EQ-5D
 - KCCQ
- STS Risk Score
- Katz Index of Independence in Activities of Daily Living

The Optimize PRO study will include a Confirmation of Qualification process conducted by Medtronic Clinical Analysts and an independent Screening Committee to review the anatomical characteristics of potential subjects identified by the sites for enrollment. Depending on whether a subject's anatomical characteristics meet entry criteria for the study, a recommendation to proceed with treatment or to re-evaluate / exit the subject will be provided to the site.

9.1.2 Enrollment

Subjects will be considered enrolled into the study at the time of Informed Consent. Due to the inclusion/exclusion criteria, not all patients enrolled in the study will be treated. All sites will be required to maintain a record of patients screened for the trial meeting general inclusion criteria who have signed the approved Informed Consent document. For subjects that do not meet study criteria, the reason for not continuing in the trial must be documented and recorded in the EDC system.

Pediatric, legally incompetent, or otherwise vulnerable patients are not eligible for the trial. Further, the Medtronic TAVR system will not be used as an emergency treatment.

Subjects must have their TAVR procedure as soon as possible and no later than 30 days post-enrollment.

9.1.3 Implant Procedure (TAVR)

Procedural aspects specific to the Medtronic TAVR system should be performed according to the Instructions for Use. Concomitant procedures including percutaneous coronary intervention (PCI) are not permitted to be completed during the index procedure.

The valve deployment will be completed in accordance to the cusp overlap technique via procedural angiogram, and the standard procedures of the implanting physicians and the TAVR clinical pathway protocol requirements noted below. This described TAVR clinical pathway should serve as a guide for accelerated discharge. Institutional clinical TAVR pathways can be followed as long as the modifications are consistent with an accelerated discharge.

Pre-procedure:

- Develop “early discharge plan” (including frailty, mental assessment, and home health if required) with multi-disciplinary team along with optimized screening checklist for first and / or second visit leading up to TAVR procedure.
- Standardize room layout – team composition in procedure room (planning with multi-disciplinary team).

Peri-Procedure:

- No pre-deployment balloon aortic valvuloplasty TAVR procedure unless medically necessary
- No planned general anesthesia
- Percutaneous and transfemoral femoral access only
- No urinary catheter
- Minimize central lines: no Swan-Ganz catheterization or internal jugular vein unless for temporary transvenous pacing

Post Procedure Recovery:

- Complete 12-lead ECG within 2 hours after the TAVR procedure
 - If no ECG changes compared to pre-procedure ECG and subject did not have pre-existing RBBB:
 - Remove all remaining lines within 2 hours of TAVR procedure
 - Repeat 12-lead ECG prior to discharge to confirm no new ECG changes
 - Refer to Appendix 19.1 Conduction Disturbance Management if new ECG changes or subject had pre-existing RBBB
- Mobilize within 4 - 6 hours of TAVR procedure
- Minimal intensive care unit (ICU) utilization: consider post-anesthesia care unit (PACU) in place of ICU or transfer straight to stepdown floor or telemetry unit

9.1.4 Prior to Discharge

- Physical examination and concomitant medications.
- NYHA classification
- 12-lead ECG (refer to Appendix 19.1 Conduction Disturbance Management for discharge 12-lead ECG requirements for subjects with conduction abnormalities)
- Laboratory tests - glomerular filtration rate (GFR), hemoglobin, international normalized ratio (INR) for subjects on warfarin, and serum creatinine
- TTE – must be done within 12 hours and 7 days post TAVR
- Adverse event review

9.1.5 Follow-Up Evaluations

All treated subjects will undergo follow-up evaluations at the following time points post procedure. All follow-up periods are defined as the number of days after the date of the index procedure.

Day 0 = day of index procedure

- 30 days (30 + 14 days)
- 12 months (365 ± 30 days)

30 Days

- Physical examination including height, weight, systolic and diastolic blood pressure, and concomitant medications.
- NYHA classification
- 12-lead ECG
- Quality of Life Questionnaires – KCCQ and EQ-5D
- In-office pacemaker interrogation for subjects implanted with pacemakers post index TAVR procedure
- Adverse event review

12 Months

- Physical examination including height, weight, systolic and diastolic blood pressure, and concomitant medications.
- NYHA classification
- 12-lead ECG
- Quality of Life Questionnaires – KCCQ and EQ-5D
- TTE
- In-office pacemaker interrogation for subjects implanted with pacemakers post index TAVR procedure
- Adverse event review

Other Evaluations

- Creatinine clearance from screening and discharge laboratory tests will be derived by the trial database system using the Cockcroft-Gault equation.
- A Modified Rankin Score assessment should be conducted at 1 and 3 months following any stroke event.

Table 2. Summary of Visit Schedule and Required Evaluations

	Screening	TAVR Procedure	Discharge	30 Days	12 Months
Informed Consent and HIPAA Authorization	X				
Clinical Assessment (Physical Assessment and Concomitant Medications)	X		X	X	X
NYHA Classification	X		X	X	X
TTE	X		X		X
MDCT Angiogram	X				
Procedural Angiogram		X			
Laboratory Test	X		X		
12-Lead ECG ¹	X		X	X	X
Modified Rankin Score ²	X				
Quality of Life Questionnaires ³	X			X	X
STS Risks Assessment	X				
Katz Index of Independence in Activities of Daily Living	X				
5-Meter Gait Speed	X				
Grip Strength	X				
Pacemaker Interrogation ⁴				X	X
Adverse Event Review		X	X	X	X

¹ Refer to Appendix 19.1 Conduction Disturbance Management for discharge 12-lead ECG requirements

² A Modified Rankin Score assessment should be conducted at 1 and 3 months following any stroke event.

³ Quality of Life Questionnaires include EQ-5D and KCCQ.

⁴ In-office pacemaker interrogations at pacemaker implant, 30-days, and 12 months and CareLink™ Transmissions at 3, 6, and 9 months required for subjects implanted with pacemakers post index TAVR procedure.

Throughout this trial, UB-04 summary bills and itemized hospital bills will be collected by the Baim Institute at select clinical sites in the US. Prior to the collection of billing information, patients will be asked to provide the information and permission to obtain such billing records for the length of their follow-up period. All related data will be kept in a secure and confidential database.

9.1.6 Additional Evaluations for Pacemaker Implants

Medtronic brand pacemakers are required to be implanted for subjects that require pacemaker implantation post the TAVR index procedure through the duration of their study participation in order to collect device data from pacemakers. Device data will be collected remotely via CareLink™ system at 3, 6, and 9 months post pacemaker implantation and during in-office pacemaker interrogations at pacemaker implant, 30-day, and 12-month follow-up visit.

For subjects that require pacemaker implantation, a final 'Interrogate All' device interrogation file must be obtained and saved in a digital format (Save-to-Media) at pacemaker implant, 30 day, and 12-month follow-up visit. One copy will be stored at the site and another copy will be sent to Medtronic (device data must not be cleared). A device interrogation (final 'Interrogate All')/Save-to-Media (or CareLink™ transmission) should also be completed at the time of study exit (prior to 12 months visit) and in the case of a death (where possible).

9.1.7 Missed Follow-Up Visits

Every effort should be made to ensure subjects return to the clinic for all protocol required follow-ups. If the subject is unable to return for an in-person clinic visit, the Investigator, or designee, should document in the subject record the reason the subject was unable to complete the visit and, if applicable, follow the requirements for deviation reporting as outlined in Deviation Handling section.

The investigator should also make every effort to contact the subject within the visit window to collect the subject's vital status as well as information related to potential adverse events, safety data, and hospitalizations.

9.1.8 Core Labs

Transthoracic echocardiography (TTE), ECGs, angiogram imaging, and external Holter monitor data (for applicable subjects) will be sent to core labs for central assessment. Further details of the echocardiography methods are provided in Appendix 19.3.

9.1.9 Informed Consent

Prior to enrolling in the trial, patients should be fully informed of the details of trial participation as required by applicable regulations, the site's IRB/REB and the Declaration of Helsinki. Informed Consent must be obtained from each patient prior to conducting any protocol-induced activities beyond standard of care, by using the Informed Consent Form (ICF) approved by that site's IRB/REB and by Medtronic, Inc. All Informed Consent Forms, including HIPAA forms and/or short form consents, must be approved by Medtronic, Inc. prior to use. The ICF must be signed and dated by the patient and by the person obtaining

the consent. Any additional persons required by the site's IRB/REB to sign the Informed Consent Forms must also comply.

Prior to the patient signing the ICF, the investigator or authorized designee will fully explain to the patient the nature of the research, trial procedures, anticipated benefits, and potential risks of participation in the trial. The investigator or delegate will allow adequate time for the patient to read and review the consent form and to ask questions. Signing the ICF serves to document the written and verbal information that the investigator or authorized delegate provides to the patient, the patient's understanding of the information, and his/her agreement to participate. The investigator or authorized delegate must document in the patient's medical records that the patient was consented and the date on which the consent was obtained. The original signed consent form will be retained in the patient's trial records and a copy of the Informed Consent Form will be provided to the patient.

Patients should give written consent before undergoing any protocol-required testing. However, if any of protocol-required baseline/screening evaluations (e.g. echocardiography, MDCT, coronary arteriography, lab work) have been performed for clinical diagnostic purposes prior to consenting, they can be used as the protocol-required exams, provided they were obtained within the protocol-required time windows and contain the necessary information.

9.2 Revisions in Patient Information and Informed Consent Form

Medtronic will inform the investigators whenever information becomes available that may be relevant to the subject's continued participation in the trial. The revised information will be sent to the investigator for approval by the IRB/REB.

9.3 Assessment of Efficacy

The following methods will be used for assessing, recording, and analyzing efficacy. Refer to section 9.1 Schedule of Events for timing of these assessments.

- STS risk score
- Heart team assessment
- MSCT
- TTE
- 12-lead ECG
- NYHA functional classification
- EQ-5D and KCCQ quality of life questionnaires

9.4 Assessment of Safety

9.4.1 Serious Adverse Events and Device Deficiencies

Serious adverse events and device deficiencies will be collected from the time of enrollment until the end of the study or until study exit, whichever comes first.

9.5 Recording Data

Trial sites will assign a unique ID number to each subject. Records of the subject/subject ID relationship will be maintained by the trial site. Individual subject medical information obtained as a result of this trial will be considered confidential.

This trial will utilize an Oracle Clinical Remote Data Capture (RDC) system that is the property of Medtronic. Required data will be recorded on electronic case report forms (eCRFs) by authorized site personnel as indicated on the Delegation Task List (DTL). Trial personnel delegated for eCRF completion and/or approval per the DTL will be trained on the use of the RDC system and thereafter provided with a user name and password to access the system. The eCRFs must be completed and/or updated to reflect the latest observations on the subjects participating in the trial. The investigator (or approved sub-investigator) will electronically sign the appropriate pages of each eCRF.

Data from the core lab will be entered into the Oracle Clinical RDC system by core lab personnel per their procedures established for the trial. The core lab physician will approve core lab eCRFs.

The Oracle Clinical RDC system maintains an audit trail of entries, changes, and corrections in eCRFs. If a person only authorized to complete eCRFs makes changes to an already signed eCRF, the investigator shall re-approve this eCRF.

All trial-related documents must be retained until notified by Medtronic that retention is no longer required. Medtronic will inform the investigator/institution when these documents are no longer required to be retained.

No trial document or image should be destroyed without prior written agreement between Medtronic and the investigator. Should the investigator wish to assign the trial records to another party or move them to another location, advance written notice must be given to Medtronic.

9.5.1 Source Documents

Entered data must be traceable to source documents. Source documentation is defined as the first time the data appear and may include all clinical records, hospital records, procedural reports, autopsy reports, and any other material that contains original information used for trial data collection or adverse event

reporting. Identified discrepancies between source documents and the eCRFs will be resolved through the on-line query resolution process per the Data Management plan.

The eCRFs may not serve as source documents. Source documentation for data elements not routinely captured in medical records (e.g. echocardiography variables, MDCT variables, catheter and procedural data variables, Heart Team assessment, Modified Rankin Score) may vary from center to center. The site may use technical worksheets if identified as source documents.

Source documents must be retained by the participating site for a period of two years after trial conclusion (or longer as required by local law) and made available for monitoring or auditing by the sponsor's representative or representatives of the FDA and other applicable regulatory agencies or IRB/REB.

The Investigator must ensure the availability of source documents from which the information on the eCRFs was derived. Where printouts of electronic medical records are provided as original source documents, or where copies of source documents are retained as original source documents, they should be signed and dated by a member of the investigation site team indicating they are a true reproduction of the original source document.

9.6 Deviation Handling

Protocol deviations will be reported regardless of whether medically justifiable, pre-approved by Medtronic, or taken to protect the subject in an emergency.

A protocol deviation is to be completed for each trial protocol deviation, including, but are not limited to the following:

- Failure to obtain Informed Consent prior to participation
- Incorrect version of the Informed Consent form used
- Failure to obtain IRB/REB approval before the start of the study
- Implanted subject did not meet inclusion/exclusion criteria
- Enrollment of subjects during lapse of IRB/REB approval

Investigators should obtain prior approval from Medtronic before initiating any change or deviation from the CIP, except where necessary to protect the life or physical well-being of a subject in an emergency situation. Such approval shall be documented in writing and maintained in the Investigator Site File. Prior approval is generally not expected in situations where unforeseen circumstances are beyond the investigator's control (e.g. subject did not attend scheduled follow-up visit).

In addition, Investigators are required to adhere to local IRB/REB procedures for reporting deviations.

Medtronic is responsible for analyzing deviations, assessing their significance, and identifying any corrective and/or preventive actions that may be warranted. Repetitive or serious investigator compliance issues may

represent a need to initiate a corrective action plan, which may include suspension of enrollment or termination of the investigator's or site's participation in the study.

9.7 Subject Withdrawal or Discontinuation

Subjects who discontinue participation prematurely will be included in the analysis of results (as appropriate) and will not be replaced in the enrollment of total trial subjects. If a subject is discontinued from the trial early, the reason for discontinuation should be documented in the subject file and a Study Exit eCRF must be completed. If discontinuation is because of safety concerns or lack of effectiveness, the subject shall be asked to be followed for collection of ongoing safety data outside the clinical investigation.

A subject will not be considered lost to follow-up unless all efforts to obtain compliance are unsuccessful. At a minimum, the effort to obtain follow-up information must include 3 attempts to make contact via telephone and if contact via phone is not successful, a traceable letter from the investigator should be sent to the subject's last known address. Should both telephone and mail efforts to contact the subject be unsuccessful, the subject's primary physician should be contacted. Subjects will then be deemed lost to follow up. All contact efforts to obtain follow-up must be documented in both the subject's medical records and on the trial eCRFs.

If a subject discontinues the trial at any time, is withdrawn from the trial early, or completes all protocol required follow-up they should continue to be followed by the implanting site according to their routine clinical practice for aortic valve patients. If, for any reason, this is not possible for a particular subject, or if a subject needs to change their follow-up site at any time point after conclusion of the trial, investigators should refer subjects to a local site with appropriate training and experience in managing patients with implanted aortic valves.

10 Risks and Benefits

10.1 Potential Risks

There are possible risks and side effects connected to the Evolut PRO TAV implant, but the risks are the same as those for an implant of the Evolut PRO TAV without participation in this study. Standard risks associated with the Evolut PRO system in the study are provided in the Instruction for Use.

Risks and events will be continuously monitored, assessed and documented by the investigator.

10.2 Potential Benefits

Participation in this clinical study will not result in any direct benefit to the patient. Trial subjects implanted with an Evolut PRO receive the same medical treatment as if they were not participating in this post-market

study. Participation contributes to expansion the knowledge base with respect to the use of the Evolut PRO system in a routine hospital setting.

10.3 Risk-Benefit Rationale

10.3.1 Measures to Mitigate Risks in the Trial Subjects

The following measures will be implemented to minimize risks to the trial subjects:

- Implanting physicians will have considerable experience with TAVR
- Study sites will have significant experience with TAVR
- Patients will undergo thorough imaging assessment during their pre-implant workup
- Patients will be rigorously followed over the course of the study

10.3.2 Alternatives

Presently, therapeutic alternatives for patients with the clinical indication targeted for the Medtronic TAVR System include the following:

- Medical therapy
- Balloon aortic valvuloplasty
- Surgical aortic valve replacement
- TAVR with a non-Medtronic system

10.3.3 Results from the Risk Analysis and Justification for the Study

TAVR is now established as a safe and effective treatment option for patients with symptomatic severe aortic stenosis who are at extreme, high, or intermediated risk for surgical aortic valve replacement. The Medtronic CoreValve™ system, the Evolut R system, and the Evolut PRO system (referred jointly as Medtronic TAVR) has been in widespread use since receiving the CE Mark in 2007, and there is now extensive published experience demonstrating the Medtronic TAVR system is fulfilling its intended role with a favorable risk/benefit ratio.⁽¹⁴⁻¹⁷⁾ Rigorous clinical trials have established its safety and effectiveness, with improved mortality and quality of life compared with medical therapy in extreme , high and intermediate risk patients.⁽¹⁻⁴⁾

There are risks to the subjects for participation in the trial, they are anticipated to be to the same as risks provided in the IFU and guideline compatible therapy outside of the context of the study (i.e. TAVR or SAVR in a commercial, non-study setting).

11 Adverse Events and Device Deficiencies

11.1 Definitions/Classifications

Serious adverse events (SAE) and device deficiencies are collected for this study. The definitions to be applied for the purposes of reporting adverse events are provided in Table 3.

Table 3. Adverse Event Definitions for Reporting Requirements

Event Type	Definition
Serious Adverse Event (SAE) (ISO14155:2011 3.37)	Adverse event that a) led to death, b) led to a serious deterioration in the health of the subject, resulting in 1) a life-threatening illness or injury, or 2) a permanent impairment of a body structure or a body function, or 3) in-patient or prolonged hospitalization, or 4) medical or surgical intervention to prevent life-threatening illness or injury or permanent impairment to a body structure or a body function, c) led to fetal distress, fetal death or a congenital abnormality or birth defect ⁽¹³⁾
Device Deficiency	Inadequacy of a medical device with respect to its identify, quality, durability, reliability, safety or performance. NOTE: device deficiency includes malfunctions, use errors, and inadequate labeling.

Notes:

- The interpretation of Seriousness will exclude certain interventions considered standard of care during hospitalization (e.g. IV hydration, certain medications delivered intravenously due to available intravenous access or NPO (nothing by mouth) status, and the delivery of electrolytes to maintain electrolyte balance or to address mild electrolyte depletion). Any nonoral medication or fluid delivery used to treat an acute physical decompensation/deterioration episode or to otherwise resuscitate a subject will be considered serious by definition in that it prevents a permanent impairment of a body structure or deterioration of the health of a subject.
- Planned hospitalization for a pre-existing condition, or a procedure required by the CIP, without serious deterioration in health, is not considered a serious adverse event.
- Hospitalization requires admission for at least 24 hours.
- Ballooning as needed during the implant procedure is standard practice and should not be considered a reintervention.

11.1.1 Evaluation and Documentation of Serious Adverse Events

Investigators are required to evaluate and document in the subject's medical records all serious adverse events (per the definitions in Table 3) observed in trial subjects from the time the TAVR index procedure is attempted until they are exited from the trial. All SAEs should be followed through their resolution.

Documented pre-existing conditions are not considered to be reportable unless there is a change in the nature or severity of the condition and meets definition of SAE per definition in Table 3. Pre-existing events

should be reported as an SAE in the situation where a new treatment has to be started or an existing treatment has to be changed to treat the adverse event and the event is accompanied with signs and symptoms.

Unavoidable events are conditions which do not fulfill the definition of an Adverse Event, meaning those medical occurrences, clinical signs (including toward abnormal laboratory findings), diseases or injuries that are not untoward in nature; specifically, those resulting from the intended injury such as the index TAVR procedure. The events listed in Table 4 are expected for patients undergoing TAVR, and do not need to be reported as AE, unless they occur outside of the stated timeframe, are otherwise considered to be an SAE according to the treating investigator, or are suspected or confirmed to be device-related.

Table 4. Non-Reportable Medical Occurrences Associated with the Index Procedure

Event	Timeframe (hours) from the Index Procedure
Short transient episode of arrhythmia (including ventricular fibrillation) <u>during</u> index procedure	0
Confusion, anxiety and/or disorientation (other than TIA/stroke) starting within 48 hours with or without medical intervention	120 (5 days)
Temporary change in mental status (other than TIA/stroke) not requiring additional medical interventions or new medical assessments (e.g. CT)	72
Dizziness and/or lightheadedness with or without treatment	24
Headache with or without treatment	72
Sleep problems or insomnia with or without treatment	120 (5 days)
Mild dyspnea or cough with or without treatment	72
Oxygen supply after extubation / "forced breathing therapy"	48
Diarrhea with or without treatment	48
Obstipation / Constipation with or without treatment	72
Anesthesia-related nausea and/or vomiting with or without treatment	24
Low-grade fever (<101.3°F or <38.5°C) without confirmed infection	48
Low body temperature	6
Pain (e.g. back, shoulder) related to laying on the procedure table with or without treatment	72
Incisional pain (pain at access site) with or without standard treatment and patient not returning to clinic to have additional treatment	No time limit
Pain in throat and/or trachea due to intubation	72
Mild to moderate bruising or ecchymosis	168 (7 days)
Atelectasis / Pleural Effusion not requiring punctuation	168 (7 days)

Event	Timeframe (hours) from the Index Procedure
Edema resulting in weight increase up to 4 kg / 9lbs from baseline	168 (7 days)

11.1.2 Evaluation and Documentation of Device Deficiencies

Device deficiency information will be collected throughout the trial and reported to Medtronic. Device deficiencies should be reported on a Device Deficiency eCRF (one for each Device deficiency) or on the AE CRF if the deficiency led to an adverse event (any untoward medical occurrence, unintended disease or injury, or untoward clinical signs).

11.2 Reporting of Serious Adverse Events

Serious adverse events and device deficiencies that occur during this trial are required to be reported to Medtronic in a timely manner via the AE or device deficiency eCRF.

In addition, Investigators are obligated to report adverse events in accordance with the requirements and timeframes per their reviewing IRB/REB and local regulations, if applicable.

The Sponsor is obligated to report adverse events and device deficiencies that occur during this trial to the IRB/REB as per local requirements.

11.3 Emergency Contact Details for Reporting SAE and Device Deficiencies

Investigators should contact their Medtronic clinical trial monitor or site manager if they have any questions regarding reportable SAEs. Medtronic will provide and maintain a listing of current contact details for each site.

12 Data Review Committees

12.1 Clinical Events Committee

A Clinical Events Committee (CEC) will provide independent medical review and adjudication of adverse event data used in the safety assessment of the device. The CEC will adjudicate, at minimum, all deaths and safety endpoint-related adverse events. The CEC will follow the recommendations of VARC II for classifying adverse events that relate to clinical safety endpoints. The analysis of the trial safety data will be based on CEC adjudicated events. Safety endpoint definitions are provided in Section 19.6 Endpoint Definitions.

Medtronic Confidential

The CEC members will be free from bias towards the trial and will be independent from both the trial and investigators and Medtronic. The committee will consist of at least 3 independent experts (non-Medtronic employed physicians) with expertise relevant to the trial. This may include experience in the areas of:

- Cardiac surgery
- Interventional cardiology
- Neurology
- Electrophysiology

13. Statistical Design and Methods

13.1 Analysis Populations

13.1.1 Enrolled Population

Within the enrolled population the following analysis sets are distinguished:

- **The as treated (AT) set:** The AT set consists of all enrolled subjects with an attempted TAVR implant procedure, defined as when the subject is brought into the procedure room and any of the following have occurred: anesthesia or conscious sedation administered, vascular line placed, TEE placed, or any monitoring line placed. Subjects will be analyzed according to their first attempted procedure. Enrolled subjects that do not receive an attempted TAVR implant are to be exited from the study.
- **The implanted set:** The implanted set consists of all the AT subjects who are actually implanted with the TAV. Subjects with an attempted implant that do not actually receive a TAV are to be exited from the study following discharge from the index hospitalization.
- **Per protocol set:** The per protocol set consists of all implanted subjects who's index procedure adhere to the TAVR care pathway as described in section 9.1.3 Implant Procedure TAVR (treated with conscious sedation, iliofemoral, no concomitant procedures, etc.)
- **Roll-in:** Roll-ins subjects will not be analyzed with the AT, implanted, or per protocol set and will be analyzed separately using descriptive statistics.

The primary analysis for the primary objective and secondary safety and effectiveness objectives will use the as treated set.

13.2 Description of Baseline Variables

Baseline demographic and clinical variables will be summarized for the AT, implanted, and per protocol sets. Continuous variables will be summarized as means, medians, standard deviations, interquartile ranges, minima and maxima and categorical variables will be summarized as frequencies and percentages.

13.3 Primary Analysis

The study objective and endpoints are descriptive, and no statistical hypothesis testing will be performed. Interim analyses will be conducted after 100 subjects are enrolled in the AT set and followed through 30 days post procedure.

Roll-in subjects will not be included in the primary analysis; however, the data will be summarized separately with descriptive statistics.

13.3.1 Primary Endpoint

The primary endpoint is the rate of all-cause mortality or all-stroke at 30 days. A Kaplan-Meier survival analysis will be performed with results summarized at 30 days and 12 months. This endpoint is descriptive, and no statistical hypothesis test will be performed.

13.4 Sample Size

The sample size for the AT population is 400 subjects and up to 46 sites in the US and Canada. The sample size for the roll-in population is up to 138 subjects. Total combined sample size with all analysis populations is up to 538 subjects.

This is not a hypothesis-driven study, therefore the sample size of up to 400 subjects was not determined by statistical sample size methods. With >25% of TAVR patients experiencing new conduction disturbances¹⁰, 400 patients will provide a sufficient sample (~100 patients) to evaluate the conduction disturbance management pathway.

13.5 Secondary Endpoints

The following are the secondary endpoints:

- Median days from index procedure to discharge
- Percentage of subjects with \geq moderate aortic regurgitation (AR) at discharge
- Rate of pacemaker implant for new onset or worsening conduction disturbance at 30 days

13.6 Additional Exploratory Endpoints

The following are additional exploratory endpoints:

- 30-day and 1-year hospital re-admission rates
- 1-year composite of all-cause mortality or all-stroke

13.7 Missing Data

Every effort will be undertaken to minimize missing data. However, some missing data is inevitable, and the trial is designed with the expectation that there may be up to 6% of primary data missing at 12 months. The reasons for missing data will be described and evaluated for assessment of possible bias. The distribution of prognostic factors between subjects with data and those without data will be examined to evaluate any potential sources of bias.

14. Ethics and Regulatory Compliance

This study will be conducted in accordance to the Evolut PRO commercially approved IFU and therefore is not considered to be a high risk study. An Investigational Device Exemption (IDE) is not required to be submitted to the FDA and a pre-approval submission is not required to be submitted to Health Canada, if appropriate.

The study will be conducted in accordance with the protocol, GCP, and ethical principles that have their origin in the Declaration of Helsinki. Each site must fulfill all local regulatory requirements prior to enrolling subjects, as applicable.

Participating sites will not be activated nor begin enrolling subjects until the required approval/favorable opinion from the local IRB/REB and regulatory agency has been obtained (as appropriate).

This trial will be publicly registered prior to first enrollment in accordance with the 2007 Food and Drug Administration Amendments Act (FDAAA) and on <http://clinicaltrials.gov> (PL 110-85, Section 810(a)).

Prior to enrolling subjects, each investigation site's IRB/REB will be required to approve the current CIP, the Informed Consent Form, and any other written information to be provided to the subjects. Study sites must also utilize IRB/REB approved Health Insurance Portability and Accountability Act (HIPAA) Authorization, when applicable.

IRB/REB approval of the clinical trial must be received in the form of a letter and provided to Medtronic before commencement of the trial at an investigation site. The approval letter must contain enough information to identify the version or date of the documents approved. IRB/REB roster or letter of compliance needs to be provided to allow verification that the investigator, other center trial staff, and/or Medtronic personnel are not members of the IRB/REB. If they are members of the IRB/REB, written documentation is required stating that he/she did not participate in the approval process. Investigators must inform Medtronic of any change in status of IRB/REB approval once the investigation site has started enrollment. If any action is taken by an IRB/REB with respect to the study, that information will be forwarded to Medtronic by the respective investigator.

15. Study Administration

15.1. Monitoring

Participating sites will be monitored to ensure compliance with the trial protocol, adherence to applicable regulations, and accuracy of trial data. Monitoring visits will be conducted primarily to ensure the safety and well-being of the subjects is preserved. Sites should provide appropriate access to the source data. Site personnel will complete eCRFs following each subject visit. Trial data submitted will be reviewed against subject charts and other sources containing original records of subject data. Source document verification will occur via a risk-based approach as outlined in the Monitoring Plan.

The progress of the trial will be monitored by:

- On-site review, as deemed appropriate by Medtronic
- Telephone communications between the site personnel (e.g., investigator, trial coordinator) and trial monitors
- Review of eCRFs and the associated clinical records
- Review of regulatory documents

Upon study completion, Site Closeout Visits will be conducted as outlined in the Monitoring Plan

Monitoring and monitoring oversight will be provided by Medtronic [REDACTED]. Representatives of Medtronic (i.e. contractors and designees) may also act as trial monitors.

Prior to the first site activation a monitoring plan will be established outlining the above activities, as well as trial materials to be supplied to sites, the process for corrective and preventive actions and Investigator disqualification procedures.

15.2. Data Management

Medtronic will be responsible for the processing and quality control of the data. Data review, database cleaning and issuing and resolving data queries will be done according to Medtronic internal SOPs and the Data Management Plan for this trial. The trial database will be developed and validated per the Data Management Plan for this trial and will employ validation programs (e.g. range and logic checks) on entered data to identify possible data entry errors and to facilitate data validation. The trial database will maintain an audit trail of all changes made to the eCRFs.

Refer to Recording Data section for further information regarding data collection and management procedures.

15.3. Direct Access to Source Data/Documents

Medtronic may conduct audits at participating clinical sites. The purpose of an audit is to verify the performance of the monitoring process and the trial conduct, independent of the personnel directly involved in the trial.

The investigator and/or institution shall permit Medtronic, regulatory bodies, and IRB/REB direct access to source data and documents.

15.4. Confidentiality

All information and data sent to parties involved in trial conduct concerning subjects or their participation in this trial will be considered confidential. Trial sites will assign a unique subject ID number (SID) to each subject. Records of the subject/SID relationship will be maintained by the trial site. The SID is to be recorded on all trial documents to link them to the subject's medical records at the site. To maintain confidentiality, the subjects' name or any other personal identifiers should not be recorded on any trial document other than the Informed Consent Form. In the event a subject's name is included for any reason, it will be masked as applicable. In the event of inability to mask the identification (e.g., digital media), it will be handled in a confidential manner by the authorized personnel.

15.5. Liability

Medtronic, Inc (including all wholly owned subsidiaries) maintains appropriate clinical trial liability insurance coverage as required under applicable laws and regulations and will comply with applicable law and custom concerning specific insurance coverage. If required, a Clinical Trial Insurance statement/certificate will be provided to the IRB/REB if required.

15.6. CIP Amendments

The investigator may propose any appropriate modification(s) of the CIP. Medtronic will review this proposal and decide whether the modification(s) will be implemented.

Medtronic will submit any significant amendment to the CIP, including a justification for the amendment to the investigators to obtain approval from their IRB/REB. The investigator will only implement the amendment after approval of the IRB/REB, and Medtronic. Administrative amendments to the CIP will be submitted to the IRB/REB for notification. Furthermore, investigators shall sign any approved amendment for agreement.

15.7. Record Retention

At a minimum, the investigator must retain records for at least 2 years or at least two years have elapsed since the formal discontinuation of clinical development of the devices. The investigator should take measures to prevent accidental or early destruction of the trial related materials.

15.8. Publication and Use of Information

Medtronic is committed to the widespread dissemination of all primary and secondary endpoint results. A Publication Plan will be implemented and followed. At the conclusion of the trial, a multisite abstract reporting the primary results will be prepared by the Principal Investigators (in collaboration with others including but not limited to the echo core lab physicians, and the CEC). A multisite publication will similarly be prepared for publication in a reputable scientific journal. The publication of the principal results from any single site experience within the trial is not allowed until both the preparation and publication of the multisite results, and then only with written permission from Medtronic.

Following analysis and presentation of the endpoint results, active participation of all participating investigators, CEC committee members, and core laboratory personnel will be solicited for data analysis and abstract and manuscript preparation. Submission of all abstracts and publications regarding the primary endpoint and secondary endpoints from the trial requires approval by the Principal Investigators after review by the Publications Committee.

A separate Publication Plan will provide detailed information about the publication committee, authorship, publication proposals, and requests for data.

15.9. Suspension or Early Termination

15.9.1 Suspension or Early Termination of the Trial

If the trial is terminated prematurely or suspended, Medtronic shall promptly inform the clinical investigators of the termination or suspension and the reason(s) for this. The investigator shall then promptly inform the reviewing IRB/REB. Medtronic will, as soon as possible, provide a written statement to the investigators to enable prompt notification of the IRB/REB. If trial enrollment is terminated early, follow-up visits will continue for all enrolled subjects.

15.9.2 Suspension or Early Termination of a Trial Site

Medtronic may decide to suspend or prematurely terminate an investigation site (e.g. in case of expiring approval of the reviewing IRB/REB, non-compliance to the CIP, or lack of enrollment). If an investigation site is suspended or prematurely terminated, Medtronic shall promptly inform the investigator(s) of the

termination or suspension and the reason(s) for this. The investigator shall then promptly inform the reviewing IRB/REB.

16. Other Institutions and Professional Services

This study will utilize an Echo Core Lab, ECG Core Lab, and a Clinical Events Committee. Information and contact details for each of these parties will be maintained in a separate document and provided to the study sites. A definitive list of all participating parties will be provided in clinical reports. In addition, a list of the names and addresses of participating institutions will be maintained and provided to the sites.

17. Version History

Version	Summary of Changes	Author(s)/Title
1.0	New Document	[REDACTED]
2.0	<ul style="list-style-type: none">Added statements regarding compliance to the TAVR Clinical Pathway and Conduction Disturbance AppendixUpdated all references from "TAVI" to "TAVR"Clarified Operator 1 and 2 minimum requirements in Participating Sites sectionRevised Heart Team composition in Heart Team sectionRemoved Heart Team eligibility assessment in Summary of Visit Schedule and Required Evaluations sectionModified the enrollment rate in the Duration and Sample Size sectionsRemoved requirement of subject meeting inclusion / exclusion criteria prior to consent in the Enrollment sectionAdded definition for signs and symptoms of aortic valve disease in Endpoints Definitions section	[REDACTED]
3.0	<ul style="list-style-type: none">Update secondary endpoint to say Percentage of subjects with \geq moderate aortic regurgitation (AR) at dischargeSubject Enrollment: Added Roll-In Subject Section:<ul style="list-style-type: none">For all participating centers, the first three subjects implanted will be considered "roll-in" subjects. The purpose of the roll-in subjects is to provide Investigators the time for training and familiarization with the protocolized implant technique. The Training and Education team will review recommendations made by the Steering Committee	[REDACTED]

Medtronic Confidential

	<p>for transition of sites from roll-in phase to as treated analysis phase.</p> <ul style="list-style-type: none"> ○ Roll-in subjects will complete in-clinical follow-up evaluations as noted in section 9.1.5 Follow-Up Evaluations however the results for the roll-in population will be analyzed separately from the primary analysis cohorts. ● Heart Team: added language stating the Heart Team should assess eligibility of the subject according to the site's standard process and payer requirements. ● Trial Organization: updated Publication Committee members to include steering committee members ● Inclusion/Exclusion Criteria: Added exclusion criteria: <ul style="list-style-type: none"> ○ Subjects with pre-existing permanent pacemaker ○ Previous aortic valve replacement ○ Exclude subjects with horizontal aorta (aortic angulation > 70 degrees per the IFU) ○ Prohibitive left ventricular outflow tract calcification ● Implant Procedure: Added statement in introduction of section. <ul style="list-style-type: none"> ○ In addition, the valve deployment will be completed in accordance to the cusp overlap technique via procedural angiography. ● Follow-Up Evaluations: Added procedural angiography during TAVR procedure in Summary of Visit Schedule and Required Evaluations table. ● Adverse Events and Definitions: <ul style="list-style-type: none"> ○ Added in AE definition table: "Ballooning as needed during the implant procedure is standard practice and should not be considered a reintervention." ○ Clarified that Serious Adverse Events and Device Deficiencies will be collected from the time of enrollment ● Statistical Design and Methods: Added potential for interim analysis in Primary Analysis. ● Sample size: 	
--	---	--

	<ul style="list-style-type: none"> ○ Updated rationale for sample size ○ Updated sample size to include roll-in subjects ● Conduction Disturbance Management Appendix: Updates to introduction section <ul style="list-style-type: none"> ○ Removed statement: An occurrence or recurrence of high-degree atrioventricular block (HAVB) or third-degree atrioventricular block (complete heart block [CHB]) (see definitions of conduction disturbances section) at any time between procedure and discharge is an indication for permanent pacemaker implantation (PPI) (refer to HAVB during the TAVR procedure section). ○ Removed reference to subjects with pre-existing pacemakers. ○ Added statement: Subjects with pre-existing conduction disturbances (eg RBBB) or new conduction disturbances may be discharged prior to the recommended timeframes with continuous ECG monitoring. Pacing wires may be removed prior to recommended timeframe and telemetry may be discontinued prior to the recommended timeframe to allow for early discharge. ○ Revised instruction for the following cohorts: <ul style="list-style-type: none"> ■ ECG changes (48 hours post op QRS remains > 150 ms, PR remains > 240 ms, or further increase of ≥ 20 ms PR compared to 24-hour post-op ECG) and ■ New LBBB (48 hours post op continuing QRS > 150 ms or PR > 240 ms): ■ Revised instruction: consider EP study to further evaluate if the subject should be implanted with a permanent pacemaker or discharge with continuous ECG monitoring system until 30-day follow-up visit. ● Endpoint Definitions: Clarified valve thrombus found at autopsy in a subject whose cause of death was not valve-related or found at operation for an unrelated indication should not be reported as valve thrombosis. 	
--	---	--

18. References

1. Popma JJ, Adams DH, Reardon MJ et al. Transcatheter aortic valve replacement using a self-expanding bioprosthesis in patients with severe aortic stenosis at extreme risk for surgery. *J Am Coll Cardiol* 2014;63:1972-81.
2. Adams DH, Popma JJ, Reardon MJ et al. Transcatheter aortic-valve replacement with a self-expanding prosthesis. *N Engl J Med* 2014;370:1790-8.
3. Reardon MJ, Van Mieghem NM, Popma JJ et al. Surgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients. *N Engl J Med* 2017;376:1321-1331.
4. Forrest JK, Mangi AA, Popma JJ et al. Early Outcomes With the Evolut PRO Repositionable Self-Expanding Transcatheter Aortic Valve With Pericardial Wrap. *JACC Cardiovasc Interv* 2018;11:160-168.
5. Lauck SB, Wood DA, Achtem L et al. Risk stratification and clinical pathways to optimize length of stay after transcatheter aortic valve replacement. *Can J Cardiol* 2014;30:1583-7.
6. Lauck SB, Wood DA, Baumbusch J et al. Vancouver Transcatheter Aortic Valve Replacement Clinical Pathway: Minimalist Approach, Standardized Care, and Discharge Criteria to Reduce Length of Stay. *Circ Cardiovasc Qual Outcomes* 2016;9:312-21.
7. van Rosendaal PJ, Delgado V, Bax JJ. Pacemaker implantation rate after transcatheter aortic valve implantation with early and new-generation devices: a systematic review. *Eur Heart J* 2018;39:2003-2013.
8. Brignole M, Auricchio A, Baron-Esquivias G et al. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). *Eur Heart J* 2013;34:2281-329.
9. Sharma E, Chu AF. Predictors of right ventricular pacing and pacemaker dependence in transcatheter aortic valve replacement patients. *J Interv Card Electrophysiol* 2018;51:77-86.
10. Auffret V, Puri R, Urena M et al. Conduction Disturbances After Transcatheter Aortic Valve Replacement: Current Status and Future Perspectives. *Circulation* 2017;136:1049-1069.
11. Urena M, Mok M, Serra V et al. Predictive factors and long-term clinical consequences of persistent left bundle branch block following transcatheter aortic valve implantation with a balloon-expandable valve. *J Am Coll Cardiol* 2012;60:1743-52.
12. Gilard M et al. Registry of Transcatheter Aortic-Valve Implantation in High-Risk Patients. *New England Journal of Medicine* 2012:1705-1715.
13. International Standard ISO 14155:2011(E). Clinical investigation of medical devices for human subjects - Good Clinical Practice.
14. Webb JG, Wood DA. Current status of transcatheter aortic valve replacement. *Journal of the American College of Cardiology* 2012;60:483-92.
15. Genereux P, Head SJ, Wood DA et al. Transcatheter aortic valve implantation: 10-year anniversary part II: clinical implications. *European heart journal* 2012;33:2399-402.

16. Buellesfeld L, Gerckens U, Schuler G et al. 2-year follow-up of patients undergoing transcatheter aortic valve implantation using a self-expanding valve prosthesis. *Journal of the American College of Cardiology* 2011;57:1650-7.
17. Ussia GP, Barbanti M, Petronio AS et al. Transcatheter aortic valve implantation: 3-year outcomes of self-expanding CoreValve prosthesis. *European heart journal* 2012;33:969-76.
18. Dubois D, Dubois, E.F. A formula to estimate the approximate surface area if height and weight be known. *Arch Intern Medicine* 1916;17:863-71.
19. Baumgartner H, Hung J, Bermejo J et al. Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice. *European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology* 2009;10:1-25.
20. Douglas PS, Waugh RA, Bloomfield G et al. Implementation of echocardiography core laboratory best practices: a case study of the PARTNER I trial. *Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography* 2013;26:348-358 e3.
21. Clavel MA, Rodes-Cabau J, Dumont E et al. Validation and characterization of transcatheter aortic valve effective orifice area measured by Doppler echocardiography. *JACC Cardiovascular imaging* 2011;4:1053-62.
22. Shames S, Koczo A, Hahn R, Jin Z, Picard MH, Gillam LD. Flow characteristics of the SAPIEN aortic valve: the importance of recognizing in-stent flow acceleration for the echocardiographic assessment of valve function. *Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography* 2012;25:603-9.
23. Miller FA, Jr. Echocardiography derived valve area of the Edwards SAPIEN aortic valve prosthesis: new methodology is required to comply with old hemodynamic principles. *Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography* 2012;25:610-2.
24. Genereux P, Head SJ, Hahn R et al. Paravalvular leak after transcatheter aortic valve replacement: the new Achilles' heel? A comprehensive review of the literature. *Journal of the American College of Cardiology* 2013;61:1125-36.
25. Pibarot P, Hahn RT, Weissman NJ, Monaghan MJ. Assessment of paravalvular regurgitation following TAVR: a proposal of unifying grading scheme. *JACC Cardiovascular imaging* 2015;8:340-60.
26. Zoghbi WA, Enriquez-Sarano M, Foster E et al. Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. *Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography* 2003;16:777-802.
27. Lang RM, Bierig M, Devereux RB et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. *Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography* 2005;18:1440-63.
28. Nagueh SF, Appleton CP, Gillebert TC et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. *Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography* 2009;22:107-33.

29. Zamorano JL, Badano LP, Bruce C et al. EAE/ASE recommendations for the use of echocardiography in new transcatheter interventions for valvular heart disease. Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography 2011;24:937-65.

19. Appendices

19.1 Conduction Disturbance Management

The following section is intended to provide consistency in the management of subject's conduction disturbance peri and post the TAVR index procedure.

All subjects are required to have 12-lead ECG within the 2 hours following the TAVR procedure and the day of discharge. The 2-hour post procedure ECG, peri-procedural rhythm abnormalities, and pre-existing conduction abnormalities will determine the pathway.

Subjects with pre-existing conduction disturbances (eg RBBB) or new conduction disturbances may be discharged prior to the recommended timeframes with continuous ECG monitoring. Pacing wires may be removed prior to recommended timeframe and telemetry may be discontinued prior to the recommended timeframe to allow for early discharge.

No ECG Changes Immediately (2 Hours) Post Procedure:

- No new ECG changes refers specifically to PR and QRS increase < 20 ms on the ≤ 2-hour post-op ECG compared to the pre-procedure ECG.
- Subjects Without Pre-Existing RBBB:
 - Temporary pacing wires can be removed within 2 hours of the TAVR index procedure with continuous telemetry for 24 hours post-op.
 - If there are no new changes between the ECG done 24 hours post-op compared to the 2-hour post-op ECG done (PR or QRS increase ≥ 20 ms), then the subject is eligible to be discharged 1-day post op. This will also apply to those patients with normal ECG pre-TAVR and PR or QRS changes not reaching the criteria for 1st degree AVB and QRS <120 ms. Refer to instructions for ECG changes if PR or QRS ≥ 20 m/s in patients with a) prior conduction abnormalities and b) with normal ECG pre-TAVR and ECG changes reaching the criteria for 1st degree AVB or QRS interval duration >120 m/s.
 - Proceed with pacemaker implantation if there is an occurrence of HAVB/CHB any time during the post-TAVR period.
- Subjects With Pre-Existing RBBB:
 - Maintain temporary pacing until after 24 hours post the TAVR index procedure.

- If there are no changes between the ≤ 2 -hour post-op ECG compared to the 24-hour post-op ECG, then the temporary pacing wire can be removed. Continue telemetry for 1 – 2 days and if there continues to be no new ECG changes then the subject is eligible to be discharged 2 – 3 days post index procedure with a continuous ECG monitoring via a Holter monitor. The subject should maintain the continuous ECG monitoring system until the 30-day follow-up visit.
- If there are ECG changes of at least ≥ 20 ms in the PR or QRS duration compared to the ECG 2-hour post-op, then refer to instructions for New ECG Changes.
- Proceed with pacemaker implantation if there is an occurrence of HAVB/CHB any time during the post-TAVR period.

ECG Changes (Increase of PR or QRS ≥ 20 ms):

- If there are ECG changes of ≥ 20 m/s in the PR or QRS duration on the ≤ 2 -hour post op ECG compared to the ECG done pre-procedure, and subjects have pre-existing RBBB, LBBB, IVCD with QRS ≥ 120 m/s or 1st degree AVB pre-procedure, then temporary pacing must be maintained until after 24 hours post the TAVR index procedure.
 - If ECG changes resolve, or there are no further changes of ≥ 20 ms between the ≤ 2 -hour post-op ECG compared to the 24-hour post-op ECG and QRS ≤ 150 m/s and PR ≤ 240 m/s, then the temporary pacing wire can be removed. Continue telemetry for 1- 2 days. If there are no further ECG changes and/or bradyarrhythmias, the subject is eligible to be discharged 2 – 3 days post index procedure with a continuous ECG monitoring via a long-term Holter monitor until the 30-day follow-up visit.
 - If there are ECG changes of ≥ 20 ms in the PR or QRS duration OR the QRS > 150 m/s or PR > 240 ms, then maintain temporary pacing for an additional 24 hours.
 - If ECG changes resolve, or no further ECG changes and QRS ≤ 150 ms and PR ≤ 240 ms then temporary pacing wire can be removed; continue telemetry for 1- 2 days. If there are no further ECG changes and/or bradyarrhythmias, the subject is eligible to be discharged 2 – 3 days post index procedure with a continuous ECG monitoring via a long-term Holter monitor until the 30-day follow-up visit.
 - Permanent pacemaker implantation may be considered if at 48 hours post-op the QRS remains > 150 m/s, PR remains > 240 m/s, or further increase of ≥ 20 m/s PR compared to 24-hour post-op ECG.
 - An EP study may be used to further evaluate the need for pacemaker implantation. Infra-Hisian block during atrial pacing or a spontaneous HV interval > 100 ms should prompt permanent pacemaker implantation.
 - In those patients with 1st degree atrioventricular block (with stable PR duration for at least 24 hours, irrespective of PR interval duration) as the only conduction abnormality and a QRS duration < 120 ms, continuous ECG monitoring at hospital discharge via a Holter monitor is preferred instead of permanent pacemaker. The subject should maintain the continuous ECG monitoring system until the 30-day follow-up visit.

- Proceed with pacemaker implantation if there is an occurrence of HAVB/CHB any time during the post-TAVR period.

New Onset LBBB Post Procedure:

- Maintain temporary pacing until after 24 hours post the TAVR index procedure.
 - If there are no changes between the ≤ 2 -hour post-op ECG compared to the 24-hour post-op ECG or the LBBB is resolved, then the temporary pacing wire can be removed and continue telemetry for 1 – 2 days:
 - If there continues to be no new ECG changes or arrhythmias and the LBBB resolves, then the subject is eligible to be discharged 2 days post index procedure without continuous monitoring.
 - If the LBBB continues and $QRS \leq 150$ ms and $PR \leq 240$ ms compared to the 24-hour post-op ECG then the subject is eligible to be discharged 2 – 3 days post index procedure with a continuous ECG monitoring via a Holter monitor. The subject should maintain the continuous ECG monitoring system until the 30-day follow-up visit.
 - If the LBBB continues and $QRS > 150$ ms or $PR > 240$ ms then consider proceeding with pacemaker implantation or an EP study to further evaluate if the subject should be implanted with a permanent pacemaker. Infra-Hisian block during atrial pacing or a spontaneous HV interval > 100 ms should prompt permanent pacemaker implantation.
 - If there are ECG changes of at least ≥ 20 ms in the PR or QRS duration between the 2-hour post-op ECG compared to the 24-hour post-op ECG, then maintain temporary pacing for an additional 24 hours.
 - If no further ECG changes compared to 24-hour ECG (PR or QRS increase < 20 ms) or LBBB is resolved, then refer to instruction noted above.
 - If the ECG changes do not resolve and there is further ≥ 20 ms in the PR or QRS duration, then proceed with implanting a permanent pacemaker.
 - Proceed with pacemaker implantation if there is an occurrence of HAVB/CHB any time during the post-TAVR period.

HAVB/CHB (transient or persistent) during the TAVR procedure:

- Maintain temporary pacing until after 24 hours post the TAVR index procedure.
 - If the subject continues to experience HAVB/CHB then proceed with implanting a permanent pacemaker.
 - If the HAVB/CHB resolves and there is not recurrent heart block, then the temporary pacing wire can be removed and continue telemetry for 1-2 days.
 - If the HAVB/CHB reoccurs then proceed with implanting a permanent pacemaker.

- If the HAVB/CHB does not re-occur and there are no new ECG changes compared to the 24-hour post op ECG, then the subject is eligible to be discharged 2 – 3 days post index procedure with a continuous ECG monitoring via a Holter monitor. The subject should maintain the continuous ECG monitoring system until the 30-day follow-up visit. Refer instructions above for any changes to the ECG.

Conduction Disturbances Definitions:

Conduction Disturbances (infra nodal block)	
Right Bundle Branch Block (RBBB)	<ol style="list-style-type: none"> 1) QRS duration ≥ 120 ms 2) rsr', rsR', rSR', or rarely a qR in leads V1 or V2. The R' or r' deflection is usually wider than the initial R wave 3) In a minority of patients, a wide and often notched R wave pattern may be seen in lead V1 and/or V2 4) S wave of greater duration than R wave or >40 ms in leads I and V6 5) Normal R peak time in leads V5 and V6 but peak R wave >50 ms in lead V1
Left Bundle Branch Block (LBBB)	<ol style="list-style-type: none"> 1) QRS duration ≥ 120 ms 2) Broad notched or slurred R wave in leads I, aVL, V5, and V6 and an occasional RS pattern in V5 and V6 attributed to displaced transition of QRS complex 3) Absent Q waves in leads I, V5, and V6, but in the lead aVL, a narrow Q wave may be present in the absence of myocardial pathology 4) R peak time >60 ms in leads V5 and V6 but normal in leads V1, V2, and V3, when small initial R waves can be discerned in the precordial leads 5) ST and T waves usually opposite in direction to predominant QRS voltage
Non-specific intraventricular conduction delay (IVCD) with QRS interval ≥ 120 ms	QRS interval duration ≥ 120 ms where morphology criteria for RBBB or LBBB are not present

Atrioventricular Block	
First-degree atrioventricular block	P waves associated with 1:1 atrioventricular conduction and a PR interval >200 ms
Mobitz I	Mobitz II heart block is characterized by progressive prolongation of the PR interval on consecutive beats followed by a blocked P wave (i.e., a 'dropped' QRS complex)

<p>High-degree atrioventricular block (HAVB)</p>	<p>HAVB is defined as any of the following:</p> <p>Second degree AV block type 2 (Mobitz II) in the presence of a QRS ≥ 120 ms</p> <p>2:1 AV block in the presence of a QRS ≥ 120 ms</p> <p>≥ 2 consecutive P waves at a constant physiologic rate that do not conduct to the ventricles</p> <p>Transient third degree AV block</p> <p>In the setting of AF, a prolonged pause (> 3 seconds) or a fixed slow (< 50 bpm) ventricular response rate</p>
<p>Third-degree atrioventricular block (Complete heart block [CHB])</p>	<p>P waves with a constant rate with dissociated ventricular rhythm (no association between P waves and R waves) or fixed slow ventricular rhythm in the presence of atrial fibrillation</p>

19.2 Quality of Life Questionnaires

Quality of Life Questionnaires used in this trial include:

- Kansas City Cardiomyopathy Questionnaire (KCCQ)
- EuroQol (EQ-5D)

These questionnaires will be provided under separate cover.

19.3 Echocardiography Procedure

19.3.1 Required Exams

Transthoracic echocardiography is required at the following intervals:

Interval	Time Window
Screening	Within 12 weeks prior to procedure
Discharge	Between 12 hours and 7 days post-procedure
1 year	Day 365 \pm 30 days

19.3.2 General Imaging and Recording Procedures

- A list of recommended images is provided in Section 19.3.3, List of Recommended Images.
- The subject's ID number and exam interval should be annotated on the image.

Medtronic Confidential

- A simultaneous ECG with a clearly defined R-wave should be displayed on all clips.
- Digital cine clips should be a minimum of two cardiac cycles in length (preferably three cycles)
- Color Doppler images should be obtained at a minimum frame rate of 20 Hz through optimization of sector width and depth settings.
- Still frames of measured variables (e.g., LVOT diameter, velocities) should be captured. In addition, still frames of spectral Doppler tracings without the measurements should be captured to facilitate analysis by the Echo Core Lab. Still frames of spectral Doppler tracings should contain a minimum of 3 cardiac cycles for subjects in sinus rhythm, and a minimum of 5 cardiac cycles for subjects in atrial fibrillation (two sequential frames per variable may be necessary).
- Spectral Doppler waveforms should be recorded at a minimum sweep speed of 50 mm/sec.
- Echocardiograms should be recorded and archived on a DICOM digital format for transmission to the Echo Core Lab.
- Exams will be transmitted to the Echo Core Lab via compact disc (CD-R) or Web-based picture archiving and communication system. Details of the image transmission process for each site will be established during site initiation process.
- Exams sent to the Echo Core Lab via CD-R should be DICOM files in a true or pure DICOM format.
- The following information should be documented on any CD-R disks sent to the Echo Core Lab:
 - Trial site ID number
 - Subject ID number
 - Exam date
 - Trial interval

19.3.3 List of Recommended Images

Parasternal long-axis window

1. 2D gray scale standard view (LV in a sagittal section)
2. 2D color Doppler for mitral regurgitation (MR)
3. 2D color Doppler of aortic (native or prosthetic) regurgitation (AR)
4. If AR is present, ZOOM & narrow sector with focus on vena contracta of regurgitant jet
5. 2D gray scale ZOOM for LV outflow tract diameter (LVOT)
6. Frozen image of measured LVOT diameter
7. 2D gray scale; ZOOM at an intercostal space higher for aortic root/aortic prosthesis

Parasternal short-axis window

8. 2D grayscale LV at mitral valve level
9. 2D grayscale LV at papillary muscle level
10. Frozen image of measured LV dimensions (without measurements)

11. 2D grayscale LV at apical level
12. 2D grayscale aortic valve level
13. 2D color Doppler of AR: post-implant start scanning from highest position and record first visible AR jet, scan more downwards and look for additional jets – confirm origin of AR jets from PLAX

Parasternal long-axis view (RV inflow)

14. 2D color Doppler of tricuspid regurgitation (TR)
15. If TR is present, CW Doppler of TR jet (frozen image without measurements)
16. Frozen image of TR jet velocity with measurements

Apical 4-Chamber window

17. 2D grayscale standard view
18. 2D color Doppler of MR
19. If MR is present, ZOOM & narrow sector
20. If MR is present, CW Doppler of MR jet (frozen image)
21. 2D color Doppler of TR
22. If TR is present, CW Doppler of TR jet (frozen image without measurement)
23. Frozen image of TR jet velocity with measurements
24. 2D grayscale focussed on LV with decreased depth
25. PW Doppler of transmitral flow at mitral valve tips (frozen image)
26. Tissue Doppler of the septal mitral annulus (frozen image)
27. Tissue Doppler of the lateral mitral annulus (frozen image)

Apical long-axis view

28. 2D grayscale standard view
29. 2D color Doppler of AR
30. If AR is present, ZOOM & narrow sector, shift Nyquist 35-40 for PISA measurements
31. If AR is present, CW Doppler of AR jet (frozen image without measurement)
32. Frozen image of CW Doppler of AR jet (with measurements)
33. CW Doppler of aortic/prosthetic valve (frozen image without measurement)
34. Frozen image of measured aortic/prosthetic valve velocity
35. PW Doppler LVOT (native aortic valve): within 0.5 – 1 cm below native aortic valve (frozen image without measurements)
36. PW Doppler LVOT (post-implant) immediately proximal to inflow of stent or valve (frozen image without measurements)
37. Frozen image: measured LVOT velocity

Apical 2-Chamber view

- 38. 2D grayscale standard view
- 39. 2D grayscale focused on LV with decreased depth

Sub-costal Position

- 40. 2D grayscale; long-axis view
- 41. 2D grayscale; short-axis view
- 42. 2D grayscale: IVC and hepatic vein
- 43. If TR moderate by color Doppler, PW Doppler of hepatic vein (frozen image)
- 44. If AR mild by color Doppler, PW Doppler from descending aorta (frozen image)

Supra-Sternal Position

- 45. CW Doppler of aortic valve velocity non-imaging probe (frozen image without measurements)
- 46. Frozen image: measured aortic valve velocity
- 47. If AR mild by color Doppler, PW Doppler from descending aorta (frozen image)

Right Parasternal Position

- 48. CW Doppler of aortic valve velocity; non-imaging probe (frozen image without measurements)
- 49. Frozen image: measured aortic valve velocity

Results Reporting

- 50. Screen prints of all results pages

19.3.4 Data Requirements

Sites should obtain the appropriate images and Doppler recordings in order for the Echo Core Lab to assess and report the variables listed below. Procedures for acquiring key variables are described in Section 19.3.5, Acquisition of Key Variables.

- Height (cm) and Weight (kg)
- Heart rate
- Left ventricular outflow tract (LVOT) diameter in mid systole
- Max aortic/prosthetic valve velocity (V_2) by CW Doppler
- Aortic valve velocity time integral (VTI) by CW Doppler
- Mean gradient across aortic valve (MGV_2) by CW Doppler
- LVOT VTI by PW Doppler
- Grade of aortic/prosthetic transvalvular regurgitation (post-implant only)
- Grade of aortic/prosthetic paravalvular regurgitation (post-implant only)
- Grade of prosthetic total (transvalvular plus paravalvular) regurgitation (post-implant only)
- Grade of mitral regurgitation

- Grade of tricuspid regurgitation
- Max tricuspid regurgitant (TR) jet velocity (if TR is present)
- Left ventricular internal dimension at end diastole
- Left ventricular internal dimension at end systole
- Interventricular septal thickness at end diastole
- Left ventricular posterior wall thickness at end diastole
- Left atrial diameter (anterior-posterior linear dimension) at systole
- Left ventricular ejection fraction by visual estimate
- Grade of diastolic dysfunction (if present)

In addition, the following variables will be derived by the central database from the appropriate measurements reported on the site eCRF.

- Body surface area (Dubois and Dubois)⁽¹⁸⁾
- Peak aortic pressure gradient
- Aortic valve area (AVA)/effective orifice area (EOA) by continuity equation
- Aortic valve area/effective orifice area index (EOAI)
- Doppler Velocity Index
- Estimated right ventricular systolic pressure (RVSP)

Derived variables will be displayed on the eCRF upon entry of the appropriate raw measurements. The pre-implant qualifying AVA must be based on the site reported variables for LVOT diameter, LVOT VTI, aortic valve VTI, height, and weight.

19.3.5 Acquisition of Key Variables

19.3.5.1 LVOT Diameter

Pre-implant LVOT diameter is measured from the inner edge to inner edge of the septal endocardium, and the anterior mitral leaflet in mid-systole (Figure 2 A and B).^(19,20) Following implantation of the TAV, LVOT diameter is measured from the parasternal long-axis view, immediately proximal to the inflow aspect of the stent, and in mid systole (Figure 2 C and D)⁽¹⁹⁻²¹⁾ Post-surgical valve implantation, LVOT diameter is measured from the junction of the anterior sewing ring and the ventricular septum to the junction of the sewing ring and the anterior mitral valve leaflet (Figure 2 E and F).⁽¹⁹⁾




Figure 2 (A) and (B) Examples of measurement of pre-implant LVOT diameter. LVOT diameter is measured from the white-black interface of the septal endocardium to the anterior mitral leaflet, parallel to the aortic valve plane, approximately 0.5 cm below the level of the aortic annulus, and in mid systole **(C) and (D)** Post TAV implantation, LVOT diameter measurement is from outer edge to outer edge of the inflow aspect of the stent **(E) and (F)** post surgical valve implantation, LVOT diameter is measured from the junction of the anterior sewing ring and the ventricular septum to the junction of the sewing ring and the anterior mitral valve leaflet.

19.3.5.2 LVOT Velocity

LVOT velocity is recorded with PW Doppler from the apical position, in either the apical long-axis view or in the anteriorly angulated four-chamber view (or “5-chamber view”). For pre-implant exams, the PW sample

Medtronic Confidential

volume should be positioned just proximal to the aortic valve, with care to avoid the zone of pre-valve acceleration (usually 0.5 to 1.0 cm proximal to the cusps, Figure 3).⁽¹⁹⁾

Post TAV implantation, the sample volume should be placed proximal to the inflow aspect of the stent.⁽²²⁾ Full-screen imaging of the TAV should be used to verify positioning of the sample volume below the stent before switching to spectral Doppler mode (Figure 3 C and D).^(22,23)

The LVOT VTI is measured by tracing the modal velocity (middle of the dense signal) for use in the continuity equation.⁽¹⁹⁾




Figure 3 (A) Sample volume placement just proximal to zone of pre-valve acceleration (illustration by Mayo Clinic, used with permission) (B) Optimal LVOT velocity signal showing a smooth spectral Doppler recording with a narrow velocity range at each time point (C) Illustration showing correct sample volume placement just proximal to inflow of TAV stent (D) Full-screen imaging of stent to ensure positioning of sample volume below the TAV stent.

19.3.5.3 Aortic Valve Velocities

Aortic valve velocity should be interrogated with CW Doppler from a minimum of 2 transducer positions (apical and either a parasternal or suprasternal position). The position that provides the highest velocity is used for measurements. A smooth velocity curve with a clear outer edge and maximal velocity should be recorded. The maximal velocity is measured at the outer edge of the dark signal; fine linear signals at the peak should not be included in measurements. The outer edge of the dark “envelope” of the velocity curve is traced to provide both the VTI for the continuity equation and the mean gradient (Figure 4).⁽¹⁹⁾




Figure 4 (A) Aortic valve velocities interrogated from multiple transducer positions (*illustration by Mayo Clinic, used with permission*) (B) CW Doppler of severe aortic stenosis showing tracing of the velocity curve from mean gradient and VTI, and measurement of max velocity.

19.3.5.4 Assessment of Prosthetic Aortic Regurgitation

An integrated exam approach using color flow, pulsed-wave (PW), and continuous-wave (CW) Doppler is used to assess the severity of transvalvular and paravalvular aortic regurgitation (AR). Color flow Doppler imaging should be performed from the parasternal long and short-axis views, and the apical long-axis and/or 5-chamber views. In the short axis view, color imaging should be performed at multiple levels (from level of the leaflets to below the skirt and frame to assess paravalvular regurgitation, and at the coaptation point of the leaflets for transvalvular (central) regurgitation).^(24,25)

If AR is seen by color Doppler, a CW Doppler recording of the regurgitant signal should be obtained for measurement of pressure half-time and assessment of jet density. If the degree of AR by color Doppler appears more than mild by visual estimate, the velocity in the proximal descending aorta should be recorded with PW Doppler.

The degree of transvalvular, paravalvular, and total (transvalvular plus paravalvular) AR will be graded as none, trace, mild, mild to moderate, moderate, moderate to severe, and severe based on the synthesis of the Doppler parameters shown in Table 5.⁽²⁵⁾ The category of “trace” should be used in cases where regurgitation is barely detectable by color Doppler. Regurgitant signals observed to originate within the stent will be considered transvalvular, and regurgitant signals observed to originate outside the stent will be considered paravalvular.



Table 5. Parameters for evaluation of the severity of aortic regurgitation

3-class Grading Scheme	Trace	Mild	Mild	Moderate	Moderate	Severe
Unifying 5-Class Grading Scheme	Trace	Mild	Mild-to-Moderate	Moderate	Moderate-to-severe	Severe
Doppler parameters (qualitative or semiquantitative)						
Jet Features						
Extensive/wide jet origin	Absent	Absent	Absent	Present	Present	Present
Multiple jets	Possible	Possible	Often present	Often present	Usually present	Usually present
Jet path visible along stent	Absent	Absent	Possible	Often present	Usually present	Usually present
Proximal flow convergence visible	Absent	Absent	Absent	Possible	Often present	Often present
Vena contracta width (mm)	<2	<2	2-4	4-5	5-6	>6
Vena contracta area (mm ²)	<5	5-10	10-20	20-30	30-40	>40
Jet width at origin (% LVOT diameter)	Narrow (<5)	Narrow (5-15)	Intermediate (15-30)	Intermediate (30-45)	Large (45-60)	Large (>60)
Jet density: CW Doppler	Incomplete or faint	Incomplete or faint	Variable	Dense	Dense	Dense
Pressure half-time (ms): CW Doppler	Slow (>500)	Slow (>500)	Slow (>500)	Variable (200-500)	Variable (200-500)	Steep (<200)
Diastolic flow reversal in descending aorta	Absent	Absent or brief early diastolic	Intermediate	Intermediate	Holodiastolic (end-diast. Vel. >20 cm/s)	Holodiastolic (end-diast.)

Optimize PRO Clinical Investigation Plan

Version 3.0

Page 61 of 82



						Vel. >25 cm/s)
Circumferential extent of PVR (%)	<10	<10	10-20	20-30	>30	>30
Doppler parameters (quantitative)						
Regurgitant volume (ml/beat)	<15	<15	15-30	30-45	45-60	>60
Regurgitant fraction (%)	<15	<15	5-10	10-20	20-30	>30
Effective regurgitant orifice area (mm ²)	<5	<5	5-10	10-20	20-30	>30

Medtronic Confidential

This document is electronically controlled

056-F275, v3.0 Clinical Investigation Plan Template

19.3.5.5 Assessment of Mitral Regurgitation

Color flow Doppler imaging of the left atrium should be performed from the parasternal long-axis view, and from the apical 4, 2, and long axis views.

Mitral regurgitant (MR) jets should be recorded with CW Doppler using a velocity scale that allows assessment of the density, shape, duration, and peak velocity of the MR jet. If the severity appears moderate or greater by visual assessment, pulmonary vein velocities should be recorded with PW Doppler to assess for the presence of systolic flow reversal. Grading of the severity of mitral regurgitation should be integrative using the parameters in Table 6.⁽²⁶⁾

Table 6. Parameters for evaluation of the severity of mitral regurgitation

Parameter	Mild	Moderate	Severe
Color flow jet area	Small, central jet (usually <4 cm ² or <20% of LA area)	Variable	Large central jet (usually >10 cm ² or >40% of LA area), or variable wall-impinging jet swirling in the LA
Jet density (CW)	Incomplete or faint	Dense	Dense
Jet contour (CW)	Parabolic	Usually parabolic	Early peaking, triangular
Pulmonary vein flow	Systolic dominance	Systolic blunting	Systolic flow reversal

19.3.5.6 Assessment of Tricuspid Regurgitation

Color flow imaging of the right atrium should be performed from the apical 4-chamber view, the parasternal long-axis view of the RVOT, and the parasternal short-axis view at the level of the aortic valve.

Tricuspid regurgitant (TR) jets should be recorded with CW Doppler using a velocity scale that allows assessment of the density, shape, duration, and peak velocity of the TR jet. If the severity appears moderate or greater by visual assessment, hepatic vein velocities should be recorded with PW Doppler to assess for the presence of systolic flow reversal. Grading of the severity of tricuspid regurgitation should be integrative using the parameters in Table 7.⁽²⁶⁾

Table 7. Parameters for evaluation of the severity of tricuspid regurgitation

Parameter	Mild	Moderate	Severe
Jet area (cm ²)	<5	5 – 10	>10
VC width (cm)	Not defined	Not defined, but <0.7	≥0.7

PISA Radius (cm)	≤0.5	0.6 – 0.9	>0.9
Jet density & contour	Soft & parabolic	Dense, variable contour	Dense, triangular, with early peaking
Hepatic vein flow	Systolic dominance	Systolic blunting	Systolic flow reversal

19.3.5.7 Assessment of Left Ventricular Function and Left Atrial Size

Dimensions of the left ventricle and left atrium should be obtained by either 2-D linear measurements or using 2-D guided m-mode from either the parasternal long or short axis views (Figure 5). Left ventricular chamber dimensions, septal thickness, and posterior wall thickness are measured using the American Society of Echocardiography (ASE) measurement convention⁽²⁷⁾ (blood-tissue interface). In addition, standard 2-D views of the left ventricle should be obtained from parasternal and apical transducer positions for visual estimation and quantitative assessment of left ventricular ejection fraction using the modified Simpson's rule, and for assessment of regional wall motion.




Figure 5. Measurements of the left ventricle (A) and left atrium (B) using 2-D guided m-mode.

19.3.5.8 Assessment of Left Ventricular Diastolic Function

A spectral Doppler recording of mitral inflow should be obtained with PW Doppler in the apical 4-chamber view, using a 1 to 3 mm sample volume placed between the mitral leaflet tips during diastole (Figure 6). The spectral gain and wall filter settings should be optimized to clearly display the onset and cessation of left ventricular inflow. The following variables should be measured:

- Mitral inflow "A" velocity
- Mitral inflow "E" velocity
- Mitral inflow E-wave deceleration time




Figure 6. Positioning of the sample volume for recording of mitral inflow velocities.

Mitral annular velocities should be obtained from the lateral and septal aspects of the mitral annulus using PW tissue Doppler (DTI) performed in the apical 4-chamber view. The sample volume should be positioned at or 1 cm within the septal and lateral insertion sites of the mitral leaflets and adjusted as necessary (usually 5 to 10 mm) to cover the longitudinal excursion of the mitral annulus in both systole and diastole. Minimal angulation (<20 degrees) should be present between the ultrasound beam and the plane of cardiac motion. The following variables should be measured:

- Mitral annular tissue Doppler systolic velocity (septal and lateral)
- Mitral annular tissue Doppler early diastolic velocity (septal and lateral)
- Mitral annular tissue Doppler late diastolic velocity (septal and lateral)

19.3.6 Core Lab Analysis

Protocol-required echocardiograms will be sent to the Echo Core lab for assessment: the data generated by the Echo Core Lab will be the primary data used for analysis and reporting. Received echocardiograms will be logged in and analyzed by the Echo Core Lab according to their procedures determined for this trial.

The Echo Core Lab will report the following variables:

- Heart rate
- Left ventricular outflow tract (LVOT) diameter in mid systole
- Max aortic/prosthetic valve velocity (V_2) by CW Doppler

Medtronic Confidential

- Aortic valve velocity time integral (VTI) by CW Doppler
- Mean gradient across aortic valve (MGV₂) by CW Doppler
- LVOT VTI by PW Doppler
- Grade of aortic/prosthetic transvalvular regurgitation (post-implant only)
- Grade of aortic/prosthetic paravalvular regurgitation (post-implant only)
- Grade of prosthetic total (transvalvular plus paravalvular) regurgitation (post-implant only)
- Grade of mitral regurgitation
- Grade of tricuspid regurgitation
- Max tricuspid regurgitant (TR) jet velocity (if TR is present)
- Left ventricular internal dimension at end diastole
- Left ventricular internal dimension at end systole
- Interventricular septal thickness at end diastole
- Left ventricular posterior wall thickness at end diastole
- Left atrial diameter (anterior-posterior linear dimension) at systole
- Left ventricular ejection fraction by visual estimate
- Grade of diastolic dysfunction (if present)
 - Diastolic function should be categorized as normal, mild dysfunction (impaired relaxation pattern), moderate dysfunction (pseudonormal filling), or severe dysfunction (restrictive filling) per the 2009 American Society of Echocardiography recommendations.⁽²⁸⁾

Qualitative grading of valvular regurgitation will be performed using the criteria described in Sections 19.3.5.4 through 19.3.4.8. For reporting the degree of prosthetic regurgitation, the grading classes may be collapsed according to the 3-class grading scheme recommended by the American Society of Echocardiography (ASE)-European Association of Cardiovascular Imaging Guidelines.^(26,29)

In addition, the following variables will be derived by the central database from the appropriate measurements reported by the Echo Core Lab:

- Peak Pressure Gradient (Peak ΔP) Across the Aortic Valve in mmHg
 $\text{Peak } \Delta P = 4 \times (V_2^2)$
Where: V_2 is the peak velocity across the prosthesis in m/sec
- Aortic Valve Area (AVA) in cm²
 $\text{AVA} = \text{LVOT diameter in cm}^2 \times 0.785 \times (\text{VTI}_{V1}/\text{VTI}_{V2})$
Where: VTI_{V1} is the velocity time integral of the left ventricular outflow tract in cm, and VTI_{V2} is the velocity time integral of the native aortic valve in cm
- Aortic Valve Area Index (AVAI) in cm²/m²

$$AVA I = AVA / BSA^*$$

Where: AVA is the native aortic valve area in cm^2 , and BSA^* is the body surface area in m^2 ¹

- Effective Orifice Area (EOA) in cm^2

$$EOA = LVOT \text{ diameter}^2 \times 0.785 \times (VTI_{V1} / VTI_{V2})$$

Where: VTI_{V1} is the velocity time integral of the left ventricular outflow tract in cm, and VTI_{V2} is the velocity time integral of the aortic prosthesis in cm

- Effective Orifice Area Index (EOAI) in cm^2/m^2

$$EOAI = EOA / BSA^*$$

Where: EOA is the effective orifice area in cm^2 , and BSA^* is the body surface area in m^2

- Doppler Velocity Index (DVI)

$$DVI = VTI_{V1} / VTI_{V2}$$

Where: VTI_{V1} is the velocity time integral of the left ventricular outflow tract in cm, and VTI_{V2} is the time velocity integral of the prosthetic aortic valve in cm

- Left Ventricular Mass (LVM) in grams

$$LVM = 0.83 \times [(LVIDD + LVPW + IVS)^3 - (LVIDD)^3] + 0.6$$

Where: LVIDD is the left ventricular internal dimension at end diastole in cm, LVPW is the left ventricular posterior wall thickness at end diastole in cm, and IVS is the interventricular wall thickness at end diastole in cm.

- Left Ventricular Mass Index (LVMI) in g/m^2 body surface area

$$LVMI = LVM / BSA^*$$

Where: LVM is left ventricular mass in g, and BSA^* is body surface area in m^2

- Estimated Right Ventricular Systolic Pressure (RVSP) in mmHg

$$RVSP = (4 \times MVTR \text{ jet}^2) + 10$$

Where: MV TR jet is the max velocity of the tricuspid regurgitant jet, and 10 = the assumed mean right atrial pressure in mmHg

- Body Surface Area* (BSA) in m^2

$$BSA = 0.007184 \times (\text{height in cm})^{0.725} \times (\text{weight in kg})^{0.425}$$

* BSA derived from height and weight reported on the site eCRF

19.4 Recommended MSCT Procedures

Multi-slice Computed Tomography (Cardiac MSCT) is used to evaluate aortic valve anatomy, determine aortic root dimensions for device sizing, and to evaluate peripheral vessel dimensions and anatomy. The

* BSA derived from height and weight reported on the site eCRF

following sections are intended as recommended guidelines for acquiring the images for assessing anatomical suitability for implantation.

19.4.1 General requirements

- Multi-detector CT scanner (64-slice minimum) with ECG-gating capability.
- ECG-gated contrast enhanced aortic root (slice thickness of ≤ 1.0 mm)
- Temporal resolution should be optimized to reduce motion artifact.
- Spatial resolution should be as high as possible (goal is smallest isotropic voxel size)

19.4.2 ECG-gated contrast enhanced scan of aortic root

Retrospective ECG-gated scans are recommended, which allows for reconstruction in various phases of the cardiac cycle and optimal evaluation of anatomic dimensions and valve morphology. Recommended scan parameters are listed in Table 8.

Prospective ECG-gated sequential scans (step-and-shoot) and high-pitch spiral scans with ECG-gating (flash spiral) are also acceptable. The following parameters are important to the optimum scan:

- Detector collimation 0.4-0.625 mm.
- Slice thickness ≤ 1.0 mm.
- The recommended coverage area is from superior to the aortic arch to inferior to the cardiac apex. The minimum required coverage area is from 50 mm above the aortic annulus to 10 mm below the aortic annulus.
- The recommended slice overlap is 0.4 mm (will result in isotropic voxels with a 20 cm field of view).

19.4.2.1 Post-processing

- Retrospective ECG-gated scans
 - Verify heart rate ECG triggers are at consistent place in cardiac cycle, edit if necessary. Additional editing/removal of arrhythmias may be performed.
 - Reconstruct at multiple phases (10 increments of 10%), with ≤ 1.0 mm slice thickness. If the system has the capability, also reconstruct a “best systolic” and “best diastolic” phase.
- Prospective ECG-gated scans (including flash spiral)
 - Reconstruct with medium soft kernel and slice thickness ≤ 1.0 mm (slice overlap of 0.4 mm recommended)

Table 8. Recommended scan parameters

Parameter	Recommendation
IV injection with iodine contrast	80-100 (320mg/ml or higher), modify per patient as appropriate

Medtronic Confidential

Injection rate	4-6 mL/sec
Bolus tracking, delay	Delay time calculated using protocol for current scanner (bolus tracking or similar) with peak of contrast concentration in the ascending aorta during acquisition.
ECG-gating	Retrospective
Scan direction	Cranial-caudal
Scan coverage	From above the aortic arch to past the cardiac apex
Detector collimation	0.4 – 0.625 mm
Pitch	0.2–0.43 adapted to the heart rate
Dose modulation	Modulation and full current between 30 and 80% of the cardiac cycle
Slice thickness	0.8 mm
Slice overlap	0.4 mm
Reconstruction kernel	Medium Smooth
Post-processing	Retrospective ECG gating reconstruction algorithm that minimizes motion artifact. Reconstruct at multiple phases (10 minimum). Reconstructed slice thickness ≤ 0.8 mm.

19.4.2.2 Required aortic root measurements

The following measurements of the aortic root are obtained for assessing anatomical suitability:

- Aortic valve annulus perimeter (measured at systole if retrospective gating is used)
- Mean sinus of Valsalva diameter (measured at diastole)
- Mean sinus of Valsalva heights (measured at diastole)

Reformatting of Images (21)

- Site image cross-hairs on aortic root in all windows where it is visible. Lock cross-hairs so they remain orthogonal for all steps.
- In the coronal window, rotate cross-hairs (horizontal line) counter-clockwise to align with virtual basal plane, (Figure 7., upper left panel).
- In the sagittal window, the horizontal line is rotated clockwise or counter-clockwise to align with virtual basal plane (Figure 7, lower left panel).
- On the newly defined double-oblique axial image, scroll up and down through the aortic root until the most caudal attachment points of the three native leaflets come into view (indicated by arrowheads in Figure 8). If one of the leaflets comes into view at a more cranial or caudal slice, adjust the coronal or sagittal cross-hairs until all three leaflets come into view on the same axial slice.
- For confirmation of the correct aortic annulus plane, scroll through the double oblique axial images starting in the mid sinus and ending at the level of the aortic annulus. The sinuses should appear to be relatively the same size at the level of the mid-sinus and the leaflets should all disappear equally at the level of the annulus.





Figure 7: Example images in original orientation (axial, coronal, and sagittal). Red curved arrow and line indicate adjustment of coronal and sagittal planes to align with aortic basal annulus.



Medtronic Confidential

Figure 8. Example images of reformatted oblique coronal (upper left), oblique sagittal (lower left), double oblique axial (upper right), and 3D reconstruction (lower right). Yellow arrowheads indicate most caudal attachment of three leaflets of the aortic valve).

Aortic annulus measurements

- Choose the cleanest systolic images for the aortic annulus measurements, either automatically (e.g., best systolic) or by manually identifying. Measurement on a diastolic image is also acceptable.
- Aortic annulus measurements should be completed on the properly reformatted double-oblique axial image at aortic annulus level.
- Trace the perimeter of the basal annulus (Figure 9, left). Place cross-hairs at site of basal annulus, create major diameter through the site, create minor diameter defined as perpendicular to major and through site (Figure 9, right).




Figure 9. Example of perimeter measurement (left) and major and minor diameter measurements (right).

Sinus of Valsalva measurements

Choose the best diastolic images for measurement of sinus of Valsalva diameters and heights from images using the same reformatting technique as described in section “Reformatting of Images.”

Sinus of Valsalva diameters

- Select the double oblique axial image where the widest portion of the three sinuses is visible.
- Measure a diameter from each commissure through the site of the root to the opposite sinus. Complete for all three sinuses (Figure 10).




Figure 20. Example of sinus of Valsalva diameters

Sinus of Valsalva heights

- The sinotubular junction is typically not co-planar with the aortic annulus. Therefore, a sinus of Valsalva height must be measured for each of the three sinuses. This height is defined as the distance between the aortic annular plane and the tallest point in the sinus.
- Choose the double oblique axial image so that it is located at the level of the aortic annulus. The reformatting line representing the double oblique axial image should now be visible in the oblique coronal and oblique sagittal images at the level of the aortic annulus.
- For the left coronary and non-coronary heights, use the oblique coronal image. For the right coronary height, use the oblique sagittal image.
- To complete the measurement, scroll through the oblique coronal or sagittal image (depending on which sinus you are measuring) and locate the heights location of the sinotubular junction. On that image, measure the distance along the path of the aortic root from the aortic annular plane, marked by the reformatting line, to the sinotubular junction (Figure 11).




Figure 31. Examples of sinus of Valsalva heights; (A) left coronary; (B) non-coronary; (C) right coronary

19.4.3 Anatomic suitability and valve size selection

Device size	Aortic annulus		Sinus of Valsalva	
	Perimeter (mm)	Mean diameter (mm)	Mean diameter (mm)	Mean height (mm)
23 mm	56.5 – 62.8	18 – 20	≥ 25	≥ 15
26 mm	62.8 – 72.3	20 – 23	≥ 27	≥ 15
29 mm	72.3 – 81.6	23 – 26	≥ 29	≥ 15

19.5 Resheath and Recapture Definitions

The following definitions are applicable to the data elements on the Implant e-CRF that address the use of the resheath and recapture feature.

Resheath attempt	An attempt to intentionally resheath only a portion of the Evolut™ PRO TAV (including the frame) into the capsule of the delivery catheter (e.g. with the intent to reposition of the valve during deployment).
Recapture attempt	An attempt to intentionally fully resheath the entire Evolut™ PRO TAV (including the frame) into the capsule of the delivery catheter until there is no gap between capsule and the tip (e.g. with the intent to enable re-crossing of the aortic valve or retrieval of the system).

Medtronic Confidential

19.6 Endpoint Definitions

Mortality	
Cardiovascular mortality	<p>Any of the following criteria:</p> <ol style="list-style-type: none"> 1) Death due to proximate cardiac cause (e.g. myocardial infarction, cardiac tamponade, worsening heart failure) 2) Death caused by non-coronary vascular conditions such as neurological events, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular disease 3) All procedure-related deaths, including those related to a complication of the procedure or treatment for a complication of the procedure 4) All valve-related deaths including structural or nonstructural valve dysfunction or other valve-related adverse events 5) Sudden or unwitnessed death 6) Death of unknown cause
Non-cardiovascular mortality	Any death in which the primary cause of death is clearly related to another condition (e.g. trauma, cancer, suicide).

Myocardial Infarction	
Periprocedural MI (≤72 h after the index procedure)	<p>New ischemic symptoms (e.g. chest pain or shortness of breath), or new ischemic signs (e.g. ventricular arrhythmias, new or worsening heart failure, new ST-segment changes, hemodynamic instability, new pathological Q-waves in at least 2 contiguous leads, imaging evidence of new loss of viable myocardium or new wall motion abnormality) AND Elevated cardiac biomarkers (preferable CK-MB) within 72 h after the index procedure, consisting of at least 1 sample post procedure with a peak value exceeding 15x as the upper reference limit for troponin or 5x for CK-MB. If cardiac biomarkers are increased at baseline (>99th percentile), a further increase in at least 50% post procedure is required AND the peak value must exceed the previously stated limit.</p>
Spontaneous MI (>72 h after the index procedure)	<p>Any of the following criteria:</p> <p>Detection of rise and/or fall of cardiac biomarkers (preferably troponin) with at least 1 value above the 99th percentile URL, together with the evidence of myocardial ischemia with at least 1 of the following:</p> <ul style="list-style-type: none"> • Symptoms of ischemia • ECG changes indicative of new ischemia [new ST-T changes or new left bundle branch block (LBBB)] • New pathological Q-waves in at least 2 contiguous leads

	<ul style="list-style-type: none"> Imaging evidence of a new loss of viable myocardium or new wall motion abnormality Sudden, unexpected cardiac death, involving cardiac arrest, often with symptoms suggestive of myocardial ischemia, and accompanied by presumably new ST elevation, or new LBBB, and/or evidence of fresh thrombus by angiography and/or at autopsy, but death occurring before blood samples could be obtained, or at a time before the appearance of cardiac biomarkers in the blood. Pathological findings of an acute myocardial infarction
--	---

Stroke and TIA	
Diagnostic Criteria	<ol style="list-style-type: none"> Acute episode of a focal or global neurological deficit with at least 1 of the following: <ul style="list-style-type: none"> change in the level of consciousness hemiplegia, hemiparesis numbness or sensory loss affecting 1 side of the body dysphasia or aphasia hemianopia amaurosis fugax other neurological signs or symptoms consistent with stroke <p>Stroke: duration of a focal or global neurological deficit ≥ 24 h; OR < 24 h if available neuroimaging documents a new hemorrhage or infarct; OR the neurological deficit results in death</p> <p>TIA: duration of a focal or global neurological deficit < 24 h, any variable neuroimaging does not demonstrate a new hemorrhage or infarct</p> No other readily identifiable non-stroke cause for the clinical presentation (e.g. brain tumor, trauma, infection, hypoglycemia, peripheral lesion, pharmacological influences), to be determined by or in conjunction with the designated neurologist Confirmation of the diagnosis by at least 1 of the following: <ul style="list-style-type: none"> Neurologist or neurosurgical specialist Neuroimaging procedure (CT scan or brain MRI), but stroke may be diagnosed on clinical grounds alone
Stroke Definitions	<ul style="list-style-type: none"> Disabling stroke: an mRS score of 2 or more at 90 days and an increase in at least 1 mRS category from an individual's pre-stroke baseline Non-disabling stroke: an mRS score of < 2 at 90 days or one that does not result in an increase in at least 1 mRS category from an individual's pre-stroke baseline
Stroke Classification	<ul style="list-style-type: none"> Ischemic: an acute episode of focal cerebral, spinal, or retinal dysfunction caused by infarction of the central nervous system tissue

- **Hemorrhagic:** an acute episode of focal or global cerebral or spinal dysfunction caused by intraparenchymal, intraventricular, or subarachnoid hemorrhage
- **Undetermined:** insufficient information to allow categorization as ischemic or hemorrhagic

Signs and Symptoms of Aortic Valve Disease	
Sign/Symptom	Definition
Aortic Valve Dysfunction	
Shortness of breath/dyspnea	A feeling of difficult or labored breathing that is out of proportion to the patient's level of physical activity
Exercise intolerance	A condition where the patient is unable to do physical exercise at the level or for the duration that would be expected of someone in his/her general physical condition, or experiences unusually severe post-exercise pain, fatigue, or other negative effects
Dizziness/syncope	Lightheadness or unsteadiness of gait or a partial or complete loss of consciousness with interruption of awareness of oneself and ones surroundings
Chest pain	Discomfort and soreness in and around the chest
Worsening Heart Failure	
Volume Overload	
Orthopnea	Dyspnea in which the person can breathe comfortably only when standing or sitting erect
Paroxysmal nocturnal dyspnea	Acute dyspnea caused by the lung congestion and edema that results from partial heart failure and occurring suddenly at night, usually an hour or two after the individual has fallen asleep.
Jugular venous distension	With the patient is positioned under 45°, and the filling level of the jugular vein determined. An abnormal response is more than 3 centimeters above the sternal angle.
Hepatomegaly	Palpation of the edge of the liver below the edge of the ribs without inspiration
Peripheral edema	Swelling of tissues, usually in the lower limbs, due to the accumulation of fluids.
Pulmonary rales	Small clicking, bubbling, or rattling sounds in the lung associated with inspiration

Abdominal-jugular reflux	An elevation of venous pressure visible in the jugular veins and measurable in the veins of the arm, produced in active or impending congestive heart failure by firm pressure with the flat hand over the abdomen.
Radiographic evidence of pulmonary edema	NA
Elevated B-type natriuretic peptide level	NA
Hypoperfusion	
Narrow pulse pressure	Pulse pressure < 30 mmHg
Hypotension	Systolic BP < 90 systolic
Renal or hepatic dysfunction	<ul style="list-style-type: none"> Rise in baseline creatinine by 25% Increase in LFT (SGOT, SGPT) > 2 times normal
Low serum sodium concentration	Serum sodium < 130 mEq/dL

Bleeding Complications	
Life-threatening or disabling bleeding	<p>Fatal bleeding (<i>BARC type 5</i>) OR</p> <ul style="list-style-type: none"> Bleeding in a critical organ, such as intracranial, intraspinal, intraocular, or pericardial necessitating pericardiocentesis, or intramuscular with compartment syndrome (<i>BARC type 3b and 3c</i>) OR Bleeding causing hypovolemic shock or severe hypotension requiring vasopressors or surgery (<i>BARC type 3b</i>) OR Overt source of bleeding with drop in hemoglobin ≥ 5 g/dL or whole blood or packed red blood cells (RBCs) transfusion ≥ 4 units* (<i>BARC type 3b</i>)
Major bleeding (<i>BARC type 3a</i>)	<p>1) Overt bleeding either associated with a drop in the hemoglobin level of at least 3.0 g/dL or requiring transfusion of 2 or 3 units of whole blood/RBC, or causing hospitalization or permanent injury, or requiring surgery AND</p> <p>2) Does not meet criteria of life-threatening or disabling bleeding</p>
Minor bleeding (<i>BARC type 2 or 3a, depending on the severity</i>)	Any bleeding worthy of clinical mention (e.g. access site hematoma) that does not qualify as life-threatening, disabling, or major
<p>*Given one unit of packed RBC typically will raise hemoglobin concentration by 1 g/dL, an estimated decrease in hemoglobin will be calculated; BARC: Bleeding Academic Research Consortium²⁹; RBC: red blood cell</p>	

Notes:

- With respect to blood transfusions, it is critical to acknowledge that a bleeding complication has to be the result of overt bleeding and cannot be adjudicated based on blood transfusions alone.

2. Pre-operative hemoglobin will be used to determine severity of bleeding events

Acute Kidney Injury (up to 7 days post procedure)	
Stage 1	<ol style="list-style-type: none"> 1) Increase in serum creatinine to 150%-199% (1.5-1.99 x increase compared with baseline) OR increase of ≥ 0.3 mg/dL (≥ 26.4 mmol/L) OR 2) Urine output < 0.5 mL/kg/h for > 6 but < 12 h
Stage 2	<ol style="list-style-type: none"> 1) Increase in serum creatinine to 200%-299% (2.0%-2.99% increase compared with baseline) OR 2) Urine output < 0.5 mL/kg/h for > 12 but < 24 h
Stage 3	<ol style="list-style-type: none"> 1) Increase in serum creatinine to $\geq 300\%$ (> 3 x increase compared with baseline) OR serum creatinine of ≥ 4.0 mg/dL (≥ 354 mmol/L) with an acute increase of at least 0.5 mg/dL (44 mmol/L) OR 2) Urine output < 0.3 mL/kg/h for ≥ 24 h OR 3) Anuria for ≥ 12 h

Vascular Access Site and Access Related Complications	
Major vascular complication	<ol style="list-style-type: none"> 1) Any aortic dissection, aortic rupture, annulus rupture, left ventricle perforation, or new apical aneurysm/pseudoaneurysm OR 2) Access site or access-related vascular injury (dissection, stenosis, perforation, rupture, arterio-venous fistula, pseudoaneurysm, hematoma, irreversible nerve injury, compartment syndrome, percutaneous closure device failure) <i>leading to death, life-threatening or major bleeding, visceral ischemia, or neurological impairment</i> OR 3) Distal embolization (noncerebral) from a vascular source requiring surgery or resulting in amputation or irreversible end-organ damage OR 4) The use of unplanned endovascular or surgical intervention associated with death, major bleeding, visceral ischemia or neurological impairment OR 5) Any new ipsilateral lower extremity ischemia documented by patient symptoms, physical exam, and/or decreased or absent blood flow on lower extremity angiogram OR 6) Surgery for access site-related nerve injury OR 7) Permanent access site-related nerve injury
Minor vascular complication	<ol style="list-style-type: none"> 1) Access site or access-related vascular injury (dissection, stenosis, perforation, rupture, arterio-venous fistula, pseudoaneurysms, hematomas, percutaneous closure device failure) <i>not leading to death, life-threatening or major bleeding*</i>, visceral ischemia, or neurological impairment OR 2) Distal embolization treated with embolectomy and/or thrombectomy and not resulting in amputation or irreversible end-organ damage OR 3) Any unplanned endovascular stenting or unplanned surgical intervention not meeting the criteria for a major vascular complication OR

	4) Vascular repair or the need for vascular repair (via surgery, ultrasound-guided compression, transcatheter embolization, or stent-graft)
Percutaneous Closure device failure	Failure of a closure device to achieve hemostasis at the arteriotomy site leading to alternative treatment (other than manual compression or adjunctive endovascular ballooning)

Note: Refer to VARC II bleeding definitions

Valve Dysfunction Requiring Repeat Procedure

Any valve dysfunction that requires repeat procedure (e.g. balloon valvuloplasty, TAVR, or surgical AVR)

Note: Repeat procedures are reported on the appropriate e-CRF

Other TAVR Related Complications

Conversion to open surgery	Conversion to open sternotomy during the TAVR procedure secondary to any procedure-related complications Conversions to open surgery will be considered serious adverse events regardless of reason for the surgical conversion.
Unplanned use of cardiopulmonary bypass	Unplanned use of CPB for hemodynamic support at any time during the TAVR procedure
Coronary artery obstruction	Angiographic or echocardiographic evidence of a new, partial or complete, obstruction of a coronary ostium, either by the Evolut™ PRO prosthesis itself, the native leaflets, calcifications, or dissection, occurring during or after the TAVR procedure.
Ventricular septal perforation	Angiographic or echocardiographic evidence of a new septal perforation during or after the TAVR procedure
Mitral valve apparatus damage or dysfunction	Angiographic or echocardiographic evidence of new damage (chordae, papillary muscle, or leaflet) to the mitral valve apparatus or dysfunction (e.g. restrictions due to the Evolut™ PRO) of the mitral valve during or after the TAVR procedure
Cardiac tamponade	Evidence of new pericardial effusion associated with hemodynamic instability and clearly related to the TAVR procedure
Valve Thrombosis (Clinical)	Any thrombus not caused by infection attached to or near the trial valve that occludes part of the blood flow path, interferes with valve function, or is sufficiently large to warrant treatment which is associated with any of the following clinical sequelae.: <ul style="list-style-type: none"> Thromboembolic complications including <ul style="list-style-type: none"> Any ischemic stroke

Medtronic Confidential

	<ul style="list-style-type: none"> ○ Any peripheral embolic event ○ ST segment elevation or Non-ST elevation myocardial infarction ● Hemodynamic impairment associated with a worsening of heart failure <p>Note: valve thrombus found at autopsy in a subject whose cause of death was not valve-related or found at operation for an unrelated indication should not be reported as valve thrombosis</p>
Valve Thrombosis (Sub-Clinical)	<p>Any thrombus not caused by infection attached to or near the trial valve that occludes part of the blood flow path or interferes with valve function, without evident clinical sequelae, causing a hemodynamic impediment meeting the following criteria:</p> <ul style="list-style-type: none"> ● Increase in aortic regurgitation to moderate to severe. <p>An increase by more than 50% of discharge mean aortic valve gradient (with the post discharge mean gradient being ≥ 20 mmHg) or a decrease in the Doppler Velocity Index (DVI) by more than 50%</p>
Leaflet Motion Abnormality (With Treatment)	<p>Possible leaflet motion abnormality identified by any imaging modality with medical therapy (e.g. anticoagulation therapy, fibrinolytic therapy or valve-related medical intervention) initiated and without significant negative change in valve function (i.e. increasing obstruction or central regurgitation).</p>
Leaflet Motion Abnormality (Without Treatment)	<p>Possible leaflet motion abnormality identified by any imaging modality without medical therapy (e.g. anticoagulation therapy, fibrinolytic therapy or valve-related medical intervention) initiated but without significant negative change in valve function (i.e. increasing obstruction or central regurgitation).</p>
Valve migration	<p>After initial correct positioning, any observed movement (upward or downward) of the Evolut™ PRO within the aortic annulus from its initial position, with or without consequences.</p>
Valve embolization	<p>The Evolut™ PRO moves during or after deployment such that it loses contact within the aortic annulus*</p>
Ectopic valve deployment	<p>Permanent deployment of the Evolut™ PRO in a location other than the aortic root</p>
Valve in Valve deployment	<p>Additional valve prosthesis is implanted within a previously implanted Evolut™ PRO because of sub-optimal device position and/or function, during or after the index procedure.</p>
Hemolysis	<p>Red cell destruction as evidenced by plasma free hemoglobin >50 mg/dl</p> <p>Minor hemolysis: No intervention required</p>

	Major hemolysis: Requires intervention (e.g. iron supplements, transfusion, invasive intervention).
Frame fracture	Visual evidence on radiography or at explant of loss of contact between elements (cells) of the stent. Minor frame fracture: Does not require intervention or is not associated with prosthetic valve dysfunction. Major frame fracture: Intervention required (e.g. reoperation, catheter re-intervention) or is associated with prosthetic valve dysfunction
TAVR Conversion to Other Percutaneous Procedure	Any conversion of the intended TAVR procedure, prior to closure to other percutaneous intervention due to technical challenges, technical contraindications to the intended procedure identified intra-procedurally or complications.
Aborted Procedure	Termination of the procedure prior to implantation of the valve due to identification of a technical contraindication, intraprocedural complications of a concomitant procedure prior to valve implantation or radiation dosage. Aborted procedures will be considered serious adverse events regardless of reason for termination of the procedure.
Reintervention – Surgical or Percutaneous	Any surgical or percutaneous interventional catheter procedure that repairs, otherwise alters or adjusts, or replaces a previously implanted valve. In addition to surgical reoperations, balloon dilatation, interventional manipulation, repositioning, or retrieval, and other catheter-based interventions for valve-related complications are also considered reinterventions. Reintervention is further subdivided into surgical and percutaneous. Relationship to the study valve will be assessed for the most current valve implanted or attempted to be implanted.

*Valve embolizations are not applicable to valve that move during the procedure but are able to be recaptured and repositioned.

Prosthetic Valve Endocarditis

Any of the following:

1) Fulfillment of the following Duke criteria (22) for definite endocarditis:

- Histologic and/or microbiologic evidence of infection at surgery or autopsy, or
- 2 major criteria, or
- 1 major criteria or 3 minor criteria, or
- 5 minor criteria

Major and minor criteria are as follows:

Medtronic Confidential

Major Criteria:

- Blood cultures positive for Infective Endocarditis (IE)
 - Typical microorganisms consistent with IE isolated from two separate blood cultures, as noted below
 - Viridans streptococci, *Streptococcus bovis*, *Staphylococcus aureus*, or HACEK group
 - Community-acquired enterococci in the presence of a primary focus
 - Microorganisms consistent with IE isolated from persistently positive blood cultures defined as:
 - At least two positive cultures or blood samples obtained >12 hours apart, or
 - All of three, or a majority of four or more separate cultures of blood, the first and last sample obtained > one hour apart
 - Single blood culture positive for *Coxiella burnetii* or an antiphase I IG antibody titer >1:800
- Evidence of endocardial involvement
 - Positive results of echocardiography for IE defined as:
 - Oscillating intracardiac mass on a valve or supporting structures in the path of regurgitant jets or on implanted material in the absence of an anatomic explantation, or
 - Abscess, or
 - New partial dehiscence of a valvular prosthesis
- New valvular regurgitation (worsening or changing or pre-existing murmur not sufficient)

Minor Criteria:

- Predisposition: predisposing heart condition or intravenous drug use
- Fever: temperature >38°C
- Vascular phenomena: major arterial emboli, septic pulmonary infarcts, mycotic aneurysm, intracranial hemorrhage, conjunctival hemorrhages, and Janeway's lesions
- Immunological phenomena: glomerulonephritis, Osler's nodes, Roth's spots, and rheumatoid factor
- Microbiological evidence: positive blood culture but does not meet a major criterion (as noted above) or serological evidence of active infection with organism consistent with infectious endocarditis.
- Echocardiographic findings: consistent with IE but do not meet a major criterion as noted above

If only 1 major and 1-2 minor criteria are fulfilled, or if only 3-4 minor criteria are fulfilled, the event will be coded as "possible endocarditis"

- 2) Evidence of abscess, paravalvular leak, pus, or vegetation confirmed as secondary to infection by histological or bacteriological studies during a re-operation
- 3) Findings of abscess, pus, or vegetation involving the Evolut™ PRO at autopsy

Prosthetic Valve Dysfunction

Medtronic Confidential

Stenosis: mild	<p>For subjects with BSA $\geq 1.6 \text{ m}^2$: Mean aortic gradient ≥ 20 and ≤ 40 mmHg, EOA ≥ 0.8 and $\leq 1.1 \text{ cm}^2$ AND/OR DVI ≥ 0.25 and ≤ 0.35</p> <p>For subjects with BSA $< 1.6 \text{ m}^2$: Mean aortic gradient ≥ 20 and ≤ 40 mmHg, EOA $\geq 0.6 \text{ cm}^2$ and $\leq 0.9 \text{ cm}^2$ AND/OR DVI ≥ 0.25 and ≤ 0.35</p>
Stenosis: moderate/severe	<p>For subjects with BSA $\geq 1.6 \text{ m}^2$: Mean aortic gradient > 40 mmHg, EOA $< 0.8 \text{ cm}^2$ AND/OR DVI < 0.25</p> <p>For subjects with BSA $< 1.6 \text{ m}^2$: Mean aortic gradient > 40 mmHg, EOA $< 0.6 \text{ cm}^2$ AND/OR DVI < 0.25</p>
Paravalvular regurgitation: moderate	Moderate paravalvular regurgitation (per echo criteria in CIP)
Paravalvular regurgitation: severe	Severe paravalvular regurgitation (per echo criteria in CIP)
Transvalvular regurgitation: moderate	Moderate transvalvular regurgitation (per echo criteria in CIP)
Transvalvular regurgitation: severe	Severe transvalvular regurgitation (per echo criteria in CIP)

Notes:

- DVI = Doppler Velocity Index (LVOT VTI/valve VTI)
- For subjects LVOT diameter $> 2.5 \text{ cm}$, the DVI criteria for significant (moderate or severe) stenosis is 0.2
- Reporting of prosthetic valve dysfunction will be based on core lab values (if available).
- Prosthetic valve dysfunction events are not reported as adverse events, unless the dysfunction is accompanied with clinical sequelae at the time of event detection, and the clinical sequelae are chronologically and physiologically associated with the dysfunction. However, prosthetic dysfunctions that are associated with adverse events, and that meet the definition of a serious adverse event, should be reported as such.